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     ABSTRACT 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive 
neuronal loss that over the years spreads from the hippocampus to the neural cortex and impairs 
memory and cognitive functions. At the cellular level AD is linked to the presence of β-amyloid 
plaques and neurofibrillary tangles but despite decades of research little is known about their 
contribution to neurodegeneration and whether they are a cause or rather a result of the disease. It 
is well established that proteasome activity is impaired in AD brains and some studies suggest that 
this could be one of the initial factors leading to development of this disorder. Defective ubiquitin 
proteasome pathway (UPP) leads to accumulation of truncated or misfolded, ubiquitinated proteins 
(Ub-proteins) that can further form insoluble aggregates such as β-amyloid plaques and 
neurofibrillary tangles. The UPP involves a multitude of components and steps. It starts with the 
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ATP-dependent E1, E2 and E3 enzymatic cascade that results in tagging targeted proteins with 
polyubiquitin chains. Subsequently, shuttling factors recognize and deliver tagged proteins to the 
proteasome for degradation. Once at the proteasome, deubiquitinating enzymes (DUBs) remove 
the polyubiquitin chain and still other proteasome subunits are involved in unfolding and 
translocating the targeted protein into the degradation chamber where it is cleaved into small 
peptide fragments. Several components of this pathway were shown to be dysregulated in 
neurodegenerative disorders. It has been recognized that enhancing UPP activity could be of 
therapeutic benefit as it would prevent or diminish accumulation of toxic proteins and possibly 
prevent neuronal death.  
The major GOAL of our studies was to investigate two new potential therapeutic targets 
for AD related to UPP function:  
a) The Usp14 deubiquitinating enzyme – we investigated whether its inhibition 
increases proteasome-dependent degradation and decreases toxicity induced by the 
endogenous product of inflammation PGJ2.                
b) The product of inflammation PGJ2 that impairs different steps of the UPP – we 
investigated whether PGJ2 induces AD-like neuronal and behavioral pathology in vivo, by 
microinfusing PGJ2 into hippocampi of young and old mice. In addition, we determined 
the potential of PACAP to overcome the deleterious effects of PGJ2. 
a) Studies with Usp14: Usp14 is a deubiquitinating enzyme that decreases proteasome-
dependent degradation rates of certain substrates by removing their polyubiquitin chain before the 
substrate is committed to degradation. This leads to premature dissociation of the substrate from 
the proteasome thus escaping degradation altogether. A recent study showed that downregulating 
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Usp14 leads to increased degradation of known proteasome substrates implicated in 
neurodegenerative diseases, such as Tau, TDP-43 and ataxin-3. In addition, IU1 (1-[1-(4-Fluoro-
phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone) is a selective Usp14 inhibitor 
that was shown to increase proteasome-dependent degradation rates and could serve as a potential 
therapeutic. These studies were conducted with the HEK (human embryonic kidney) cell line and 
murine embryonic fibroblasts (MEFs), and not with primary neurons.  
We investigated the therapeutic potential of targeting Usp14 with IU1 in a more relevant 
cell model for AD, which is rat E18 cerebral cortical neuronal cultures. The results of our studies 
were most unexpected. We established that IU1 treatment indeed diminishes the levels of 
polyubiquitinated proteins but not due to enhanced proteasome-dependent degradation. Instead 
IU1 prevented the formation of polyubiquitin chains. IU1 blocked mitochondrial complex 1 which 
resulted in mitochondrial impairment and drastically lowered ATP levels. Such low levels of ATP 
are insufficient to activate the E1 enzyme of the ubiquitination cascade. E1 carries-out the first 
step that is responsible for activating ubiquitin. By assessing E1~Ub thioester formation, we 
confirmed that IU1-treatment lowers E1 activity resulting in low levels of Ub-proteins. Initially it 
may have appeared that IU1 treatment indeed sped up protein clearance by the proteasome. 
However, our observation that IU1-treatment lowered 26S proteasome levels with a concomitant 
increase in 20S proteasomes, suggested that there was not enough ATP in the cell to assemble 26S 
proteasomes and ensure their optimal activity.  
Overall, we showed that IU1, a potential therapeutic that was intended to prevent the 
accumulation of ubiquinated proteins, did not increase proteasome-dependent degradation.  
Instead, IU1-treatment blocked the ubiquitination cascade by inhibiting the mitochondrial complex 
1 and depleting ATP levels. 
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Our additional studies demonstrated that downregulating Usp14 with siRNA in rat cortical 
cultures, or Usp14 loss in cortical cultures from Usp14axJ mice, did not improve the rates of Ub-
protein degradation. Our results are of high importance to the development of potential 
therapeutics that target the UPP because of its relevance to AD.  
b) Studies with the product of inflammation PGJ2: Although UPP impairment has been 
linked to the development of AD, it is still not known what triggers it. Studies point to chronic 
neuroinflammation as a major contributing factor. Traumatic brain injury (TBI) and stroke both 
induce neuroinflammation and increase the probability of developing AD. Chronic 
neuroinflammation, as opposed to its acute version, wreaks havoc in the cells, perpetuating the 
cycle of synthesis of toxic prostaglandins and continual activation of pathways that lead to 
neuronal demise. Prostaglandin J2 (PGJ2) is an endogenous product of inflammation and is 
released by activated microglia, astrocytes and neurons as a part of the immune response. Previous 
work from our lab confirmed that PGJ2 is the most toxic of the prostaglandins tested and induces 
AD-relevant neuropathological changes at the molecular and cellular levels. Firstly, PGJ2 activates 
caspase-3 and leads to caspase-3-dependent Tau cleavage at Asp421, which leads to formation of 
aggregation prone ΔTau, the major component of neurofibrillary tangles. Secondly, PGJ2 leads to 
the accumulation and aggregation of ubiquitinated proteins in plaques and tangles, which are AD 
hallmarks. Thirdly, PGJ2 perturbs the UPP (a) by causing 26S proteasome dissociation of the 
regulatory and core particles due to carbonylation of the Rpt5 subunit, thus decreasing the levels 
of 26S proteasomes, and (b) by inhibiting DUBs such UCHL-1. PGJ2 can exert its function via 
two mechanisms. The first mechanism involves covalent modification of exposed cysteine 
residues in proteins leading to the formation of Michael adducts. The second mechanism is 
mediated by receptor binding, including the DP2 and PPARγ receptors.  
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PGJ2 is a product of the pro-inflammatory enzymes cyclooxygenases, including 
cyclooxygenase-2 (COX-2), the levels of which increase in AD brains and negatively affect 
neuronal function. COX-2 catalyzes the synthesis of prostaglandins, some of which are 
neuroprotective while others are neurotoxic. Treatment with non-steroidal anti-inflammatory 
drugs (NSAIDs), which target cycloxygenases, is one of the therapeutic strategies aimed at 
minimizing neuroinflammation. However, this anti-inflammatory strategy can produce adverse 
effects, including renal failure, heart attack and stroke, as well as preventing the synthesis of 
neuroprotective prostaglandins. Therefore, identifying a therapeutic target that is downstream of 
cyclooxygenases would be beneficial to prevent the effects of neurotoxic prostaglandins, without 
interfering with the neuroprotective ones. Targeting PGJ2, shown to induce AD-like pathology in 
cerebral cortical neuronal cultures, could offer a better strategy to prevent inflammation-dependent 
neurotoxicity. 
We investigated whether or not PGJ2 elicits AD-like pathology in vivo by injecting it into 
the CA1 hippocampal brain region in mice. Since aging is a major risk factor in sporadic AD (sAD) 
we treated old (52 weeks of age) and young (12 weeks of age) mice to determine if advanced age 
can make them more susceptible to PGJ2-linked toxicity. Our studies revealed that PGJ2 impairs 
learning and memory retention in old but not in young mice as assessed with the radial 8-arm maze 
(RAM) test. Additionally, PGJ2 induced neurodegeneration that spanned from the CA1 to the CA3 
hippocampal region in old but not young mice. Lastly we investigated the levels of dendritic spines 
as their increased numbers are associated with learning and memory. However, the decrease in 
dendritic spine levels is linked to memory impairment associated with neurodegeneration.  We 
showed that PGJ2-treatment induced dendritic spine changes in old but not in young mice. 
Compared to young mice, old mice displayed significantly less plastic, immature spines associated 
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with learning, which could explain their poor performance during the RAM test. Therefore, our in 
vivo studies showed that PGJ2 hippocampal injections induced AD-like symptoms and pathology 
in the mice.  
Lastly, we co-injected the group of old mice (53 weeks of age) with PGJ2 and PACAP27 
to determine if some of the PGJ2-induced pathological symptoms could be prevented.  PACAP is 
a neuroprotective peptide that acts through activation of the cAMP/PKA pathway.  PACAP is 
abundant in the brain and its levels decrease during neurodegeneration. We subjected the mice to 
RAM training and found learning improvement in mice co-administered PGJ2+PACAP compared 
to mice treated with PGJ2 alone, although this change was not statistically significant. These 
results indicate that PGJ2 is indeed an effective therapeutic target, and that targeting PGJ2 to 
prevent/treat AD could potentially be more efficient than targeting COX-2. 
In conclusion, we investigated two potential therapeutic approaches for AD: a) increasing 
UPP activity, and b) preventing inflammation-based toxicity by focusing on PGJ2, a product of 
cyclooxygenases. Our studies showed that IU1 is not an effective therapeutic for neurons due to 
its off-targeting effects on mitochondrial complex 1.  Moreover, genetically downregulating Usp14 
is not sufficient to induce significant changes in proteasome-dependent degradation rates. Perhaps 
combining this strategy with another neuroprotective therapeutic or peptide, such as PACAP, 
would improve the results. Lastly, we showed that PGJ2 by itself induces AD-like pathology in 
vivo that could be partially prevented by PACAP. PGJ2 could be a better and more directed 
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  Interfering with the UPP has recently provided a promising therapeutic approach for 
treatment of numerous disorders including neurodegenerative diseases. Targets are varied and 
include the proteasome, E1, E2 and E3 enzymes as well as many DUBs. Some of the therapeutics 
directed at the proteasome, usually targeting the β5 and/or β1 subunits, have even found their way 
into clinical trials in cancer therapy, like carfilzomib (Phase III against relapsed multiple 
myeloma), MLN9708 (Phase I), CEP18770 (Phase I) and the natural product NPI-0052 (Phase I). 
The UPP is involved in maintaining cellular homeostasis at several levels, like regulating cell cycle 
progression, apoptosis, various signaling pathways and finally removal of dysfunctional proteins. 
Abnormalities in any of the steps involved in the cascade of events leading to proteasome-
dependent degradation result in different disorders so the targets vary. With respect to 
neurodegenerative diseases that result from abnormal accumulation of toxic proteins it would be 
beneficial to aim at a factor that would preserve or enhance proteasome function. Targeting Usp14 
seems to be a promising therapeutic strategy in AD, since inhibiting the deubiquitinating activity 
of Usp14 in different cell lines results in increased degradation of several proteins including Tau 
which is relevant to AD.  Usp14 exhibits ubiquitin chain trimming activity that can lead to the 
dissociation of protein substrates from the proteasome, if the ubiquitin removal is faster than the 
competing steps leading to substrate degradation. The finding that Usp14 inhibition results in 
increased degradation of Tau, the accumulation and aggregation of which is strongly associated 
with AD pathology seems to be a very interesting prospect that has to be investigated further in 
primary neuronal cultures. Inhibition of Usp14 was achieved with the small molecule inhibitor 
IU1: 1-[1-(4-Fluoro-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone [101]. IU1 




substrates, like cyclin B or TDP-43 presumably by inhibiting chain trimming activity thus 
preventing proteins targeted for degradation from premature dissociation from the proteasome. 
Our studies established that high concentrations of IU1 (HIU1, 75µM) reduce the accumulation of 
Ub-proteins induced by the endogenous product of inflammation, prostaglandin J2 (PGJ2) in 
primary neuronal cultures while low IU1 concentrations (25µM) had no effect. Additionally, we 
showed that treatment with HIU1 resulted in (a) decrease in ATP levels, (b) a decline in 26S 
proteasome activity and levels with a concomitant increase in 20S proteasome, (c) calpain 
activation and calpain-mediated Tau cleavage. These data suggested that apart from the presumed 
effect on proteasomal degradation rates, IU1 also affects mitochondria. This was confirmed by 
testing mitochondrial respiratory chain complex activities which revealed that IU1 specifically 
inhibits complex I thus leading to overall cellular demise. Investigating mechanisms by which 




Figure 1. Ubiquitination and degradation of 
proteins by the ubiquitin/proteasome pathway 
(UPP). Protein ubiquitination is a complex ATP-
dependent process in which ubiquitin (Ub) is 
sequentially activated by ubiquitin-activating 
enzymes (E1), transferred to ubiquitin-
conjugating enzymes (E2) and ligated to protein 
substrates by ubiquitin ligases (E3). Polyubiquitin 
chains are formed by isopeptide bonds between 
Gly76 and Lys48 on adjacent ubiquitin molecules. 
Once a protein is polyubiquitinated, it is degraded 
rapidly by the 26S proteasome. Deubiquitinating 
enzymes (DUB) remove and disassemble 
polyubiquitin chains (scheme by Dr. Vita Vernace, a 




1.2.    THE UBIQUITIN-PROTEASOME PATHWAY 
The UPP requires most proteins to be tagged by ubiquitin to target them for degradation. 
Proteolysis by the UPP involves two major steps: ubiquitination and degradation (Figure 1). A de-
ubiquitination step also plays important role in this pathway as it edits the ubiquitination state of 
proteins and removes the ubiquitin tag for recycling. Our studies were aimed at increasing 26S 
proteasome-dependent degradation rates. 
The 26S Proteasome: Covalent binding of 
ubiquitin to proteins marks them for degradation 
by the ubiquitin/ATP dependent proteinase known 
as the 26S proteasome. The latter is a 
multicomponent enzymatic complex with a native 
molecular mass of approximately 2000kDa [22]. 
The 26S proteasome complex is composed of two 
major particles (Figure 2): (1) A cylinder-like 
structure, known as the 20S proteasome that is 
located in the center and comprises the proteolytic 
core of the enzyme, and (2) a regulatory component 
known as the 19S particle (PA700), which may be attached to each end of the cylinder-like 20S 
proteasome (reviewed in [33]).  
The 19S particle is a multicomponent complex itself containing at least 17 subunits and 
can be further divided into two subcomplexes: the base and the lid. The base confers ATPase 
activity and consists of six AAA ATPase subunits (Rpt1-Rpt6) and two non-ATPase subunits 
Figure 2. The 26S proteasome. Its two major 
particles, the 20S particle (20S proteasome) which 
is the catalytic core and the 19S particle (PA700) 
which is the regulatory component, require ATP 
binding to assemble into the 26S proteasome. The 
crystal structure of the 20S proteasome was 




(Rpn1 and Rpn2). The lid is made up of eight non-ATPase subunits (Rpn3, Rpn5-9, Rpn11, and 
Rpn12) which can specifically bind polyubiquitin-tagged substrates and also deubiquitinate them 
[33]. Rpn10 helps to tether the lid and the base, and is a receptor for polyubiquitinated substrates 
[59,59]. 
The eukaryotic 20S proteasome consists of 28 subunits, which are arranged in four 
heptameric stacked rings forming a barrel-like structure, each consisting of 7 protein subunits. The 
-type subunits, comprising the two outer rings of the 20S proteasome, provide binding sites for 
regulatory particles and form a gated channel leading to the inner proteolytic chamber. The -type 
subunits contain the active sites of the 20S proteasome. The whole particle is a dimer with an 
7777 subunit arrangement (reviewed in [33]).  
The 20S particle may be alternatively capped by other complexes, including the 11S 
activator (PA28). PA28 is a cytoplasmic complex formed by equal, stoichiometric amounts of two 
different 28 kDa subunits, PA28α and PA28β, forming a 200 kDa heterohexamer. PA28 capped 
20S proteasomes prefer substrates that are partially degraded proteins and peptides, rather than 
intact polyubiquitinated molecules [37,61]. 
Proteasome Assembly: The 19S particle guides proteins into the 20S proteasome chamber where 
unfolded proteins are degraded into short peptides (of 8-9 amino acids). Association between the 
19S RP and 20S CP is a dynamic process and requires ATP binding [112]. During degradation of 
one substrate molecule by the 26S proteasome, it was calculated that 300–400 ATP molecules are 
hydrolyzed. Substrate binding activates ATP hydrolysis, which promotes three processes: 




is necessary for the rapid association/dissociation of the 26S proteasome from/into the 19S particle 
and 20S proteasome [4].  
Multiple assembly chaperones are required in different stages of proteasome assembly. 
During 20S proteasome assembly in mammalian cells, PAC1-PAC4 (Proteasome assembly 
chaperone 1-4) bind to early-assembly intermediates of proteasome α-subunits and promote α-ring 
formation [158]. Specifically, the PAC1-PAC2 heterodimer remains attached to the nascent α-ring 
and suppresses premature α-ring dimerization, thereby promoting attachment of β-subunits to the 
proper surface of the α-ring. The PAC3-PAC4 complex then dissociates from the α-ring due to 
steric hindrance with the β3 subunit [73]. The following steps require the assistance of another 
chaperone, POMP (proteasome maturation protein). POMP inhibits the premature β-ring 
dimerization until the β7 subunit is properly incorporated [106]. In yeast, it is found that these 
premature complexes are in association with proteasome activators (PA), either Blm10 (ortholog 
of human PA200), or with the 19S RP (PA700) [151]. Dimerization of two half-proteasomes is 
triggered by incorporation of the β7 subunit, which stabilizes the nascent proteasome via its long 
C-terminal extension together with Blm10. Subsequently, with the autocatalytic maturation of β-
subunits, the nascent 20S proteasome is activated, leading to degradation of POMP and PAC1-
PAC2. Mature 20S proteasomes function as templates for the initial assembly of the 19S RP.  
Compared with 20S proteasome assembly, little is known about the mechanism of 19S RP 
assembly. The RP is subdivided into lid and base subcomplexes. A recent study [51] demonstrated 
the role of four conserved assembly factors in the yeast RP base assembly, including Hsm3 
(ortholog of human S5b), Nas2, Nas6, and Rpn14. These chaperones interact directly with Rpt1-
Rpt6 (Proteasome regulatory particle 1-6) subunits. Nas2 is released after the base precursor is 




the three other chaperones, Hsm3, Nas6 and Rpn14, are released when 20S CP associates with RP 
precursors.  
As for 26S proteasome assembly, two proteins were proposed to facilitate this process: 
Blm10 and Nob1. Blm10/PA200, a 200 kDa α-helix-rich repeat protein, is found attached to the 
20S α-surface and apparently activates some proteolytic properties by gating the entrance pore 
[144,164] [83]. Nob1, a nuclear protein in yeast present only during the cell-growing phase, 
associates with the 19S RP and is degraded just after the doubly capped 26S proteasome is [189]. 
It is suggested that Nob1 might be required for the nuclear translocation of the 20S [159].  
The Three Peptidase Activities of the 20S Proteasome: Among the 14 different subunits (7  
and 7 ) of the 20S proteasome, only three of them exhibit active sites for peptide bond hydrolysis, 
namely 1 (caspase-like), 2 (trypsin-like) and 5 (chymotrypsin-like). The chymotrypsin-like 
activity cleaves after amino acids with large or hydrophobic side chains, the trypsin-like activity 
cleaves after basic residues, and the caspase-like activity is a post-glutamyl activity that cleaves 
after acidic amino acids [142]. The 5-associated chymotrypsin-like activity seems to be the initial 
and rate-limiting step in protein degradation by the 20S proteasome [90]. The 20S proteasome is 
a threonine protease in which the nucleophilic attack is mediated by the N-terminal Thr [62]. The 
three  subunits (1, 2 and 5) bearing the active sites are first synthesized as precursor proteins 
each containing a propeptide at the N-terminus which must be cleaved off for the subunits to 
become catalytically active [165]. Processing of the three catalytically active subunits into mature 
forms occurs only after their incorporation into 20S proteasomes. 
Proteasome Activation: One of the major challenges that we are faced with is to figure out how 




on developing therapeutic strategies that will enhance degradation of oxidatively-modified and 
toxic proteins generated by a lifetime’s worth of environmental damage, without compromising 
the normal function of the UPP. One of the most appealing targets is the proteasome, the biogenesis 
of which is a highly organized multistep event. It appears that in eukaryotes the cellular level of 
active proteasomes is regulated at the level of assembly.  
(1) Genetic Activation of the Proteasome: The stable overexpression of the β5 subunit in 
primary human fibroblasts results in elevated levels of other β subunits, and increases the levels of 
all three proteasome activities [19]. This genetic manipulation results in increased survival against 
oxidants and a delay in senescence. The same group in a follow up study achieved proteasomal 
up-regulation via overexpression of the POMP protein, the accessory factor for proteasome 
assembly in humans [18]. POMP overexpression in fibroblasts led to increased levels of assembled 
and functional proteasomes, and enhanced the capacity to effectively cope with various oxidative 
stressors. These data further strengthen the prospect of genetic manipulation of the proteasomal 
system. 
(2) Proteasome activation by natural or synthetic compounds: SDS and some fatty 
acids were shown to stimulate proteasome activity in vitro by favoring the open conformation of 
the proteasome [26]. In addition, some proteasome-activating hydrophobic peptides bind as 
modifiers at non-catalytic sites, thus mimicking the effect of the 11S complex by opening the gate 
of the α-rings [91]. Katsiki et al., isolated oleuropein, the most abundant phenolic compound in 
Olea europaea leaf extract, olive oil, and olives, and demonstrated that it has a stimulatory impact 
on proteasome activity in vitro, probably acting through conformational changes of the gate of 20S 




to enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway, 
resulting in increased protection against various oxidants [99,99].  
1.3.  IU1 – A SMALL MOLECULE INHIBITOR OF Usp14  
Accumulation and aggregation of 
misfolded proteins is a common feature 
of many neurodegenerative diseases 
[138]. Increased levels of ubiquitinated 
and oxidized proteins including 
ubiquitinated Tau found in brains of AD 
patients point to impairment of the ubiquitin proteasome pathway (UPP) [62]. The UPP is essential 
for maintaining cellular homeostasis as it ensures degradation of dysfunctional proteins and 
regulates many physiological processes.  However, its efficacy declines with age and in 
neurodegeneration, therefore any means that preserve proteasome activity will serve as a strategy 
to delay/prevent the   onset of neuropathological symptoms. Recent findings show that it can be 
achieved by inhibiting the deubiquitinating enzyme Usp14 with a small molecule IU1 [101].  
Mammalian proteasomes are associated with three DUBs: Rpn11, Uch37 and Usp14. 
Rpn11 is a stoichiometric subunit of the proteasome unlike Uch37 and Usp14 which are only 
reversibly associated with it [48]. Rpn11-dependent deubiquitination is linked to translocation and 
degradation as the substrate will be deubiquitinated only after it has committed to degradation 
[193]. Such commitment step is absent in Uch37 and Usp14-dependent mode of action [65,100]. 
Both of them shorten the ubiquitin chain from the distal tip prior to substrate degradation rather 
than en bloc as is the case with Rpn11. Apparently, tagged substrates can dissociate from the 
proteasome and thus escape degradation if the rate of chain trimming is faster than the rate leading 




to protein degradation. This can contribute to accumulation of dysfunctional proteins. Usp14 slows 
down degradation of several proteasome substrates, such as Tau, cyclin B, and TDP-43 [104]. Its 
catalytic mutant shows much less inhibition implicating that it is the chain trimming action that 
slows down substrate degradation. These observations led to the screening of small molecules that 
would be capable of inhibiting the catalytic activity of Usp14. 1-[1-(4-Fluoro-phenyl)-2,5-
dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone, known as IU1, seems to specifically inhibit 
Usp14 when screened against a panel of DUBs [104]. IU1 inhibits ubiquitin chain trimming 
concomitant with increased degradation of several proteins. The effect of IU1 was tested in vitro 
and in vivo in murine embryonic fibroblasts (MEFs) and the HEK293 cell line on a number of 
proteasome substrates including Tau. The results suggest that IU1, a small molecule inhibitor of 
Usp14, enhances the degradation of proteasomal substrates. Subsequent experiments on usp14-/- 
MEF cell cultures confirmed that increased degradation rates were due to inhibiting Usp14 with 
IU1 since treatment of usp14-/- MEF with IU1 stabilized Tau and TDP-43 as well as levels of 
ubiquinated proteins rather than cause more efficient degradation. IU1 also proved to be effective 
in increasing clearance of oxidized proteins induced by menadione or H2O2 treatment[104].  
Overall these studies strongly support that IU1 effectively enhances proteasome-dependent 
degradation, a feature that can be applied to eliminating toxic proteins. However, if IU1 is to be 
used in a clinical setting, its effects need to be assessed in neurons to establish its potential as a 






1.4. INTERPLAY BETWEEN UPP AND MITOCHONDRIA: ITS ROLE IN 
NEURODEGENERATION  
Cellular homeostasis and viability strongly depend on optimal mitochondrial and ubiquitin-
proteasome pathway (UPP) 
function. Impairment of the UPP, 
mitochondrial activity and 
oxidative stress are implicated in 
aging and neurodegenerative 
diseases. Recent studies showed 
that interfering with the UPP or 
mitochondria results in 
pathological conditions and can 
lead to cell death. The UPP 
depends on mitochondria for ATP production which is needed for (a) ubiquitin activation by the 
E1 enzyme, the first step of the ubiquitination cascade, and (b) proteasome-mediated protein 
degradation as substrate unfolding and translocation into the degradation chamber, as well as 
assembly of the 26S proteasome are energy-dependent processes [112].  Mitochondrial integrity, 
on the other hand depends on UPP-mediated protein quality control. Among the many proteins 
targeted for degradation by the proteasome are aberrant mitochondria-destined proteins and 
proteins involved in maintaining balance between mitochondrial fusion and fission, like Fzo1, a 
protein involved in  mitochondrial fusion or  Fis1 and Drp1, essential components of mitochondrial 
fission machinery [119]. Numerous studies demonstrated that proteasome inhibition results in 
accumulation of ubiquinated mitochondrial proteins and impaired mitochondrial dynamics like 
increased/decreased fragmentation, aggregation or mitochondrial swelling which is detrimental to 




the cell . UPP is also involved in the turnover of mitochondria by means of the E3 ubiquitin ligase 
- Parkin, which is recruited to damaged mitochondria to mediate mitophagy [136]. The link is 
further confirmed by the presence of UPP components in the outer mitochondrial membrane which 
participate in mitochondrial dynamics [21,133,136]. These include ubiquitin ligases MITOL and 
MULAN as well as deubiquinating enzyme Ubp16/USP30 [105,134]. There is therefore, a 
crosstalk between mitochondria and the UPP in a healthy neuron and its maintenance is essential 
to ensure homeostasis, cellular health and viability. Accordingly, if one component of this system 
sustains damage it compromises the activity of the other component and this event has a negative 
impact on the entire cell and can result in apoptosis or necrosis.  
The ubiquitin/proteasome pathway (UPP) plays a critical role in aging and in the 
pathogenesis of AD [155] High levels of oxidized proteins detected in the aging brain as well as 
in brains of AD patients are an indication of proteasome impairment, since this proteolytic complex 
degrades the majority of oxidatively modified proteins [63]. Moreover, the accumulation and 
aggregation of Ub-proteins detected in most neurodegenerative disorders, such as AD, is also a 
sign of UPP dysfunction, since this pathway degrades Ub-proteins [79]. Dysfunctional 
mitochondria contribute to oxidative stress by ROS production. Oxidative stress induced by ROS 
alters the structure of cellular proteins [180] which, if not repaired, must be removed by proteolysis 
to prevent their accumulation and aggregation. Impaired clearance of oxidatively modified 
proteins can promote progression of the neurodegenerative process [63]. One of the major roles of 
the proteasome is to degrade oxidatively modified proteins, but if the oxidative stress persists it 
leads to accumulation and later aggregation of oxidized proteins which compromise proteasomal 
activity. The proteasome is also susceptible to oxidation, and oxidative modification of its Rpt3 




ubiquitin/ATP-dependent proteolysis by the 26S proteasome [81]. This is an important issue since 
there is ample evidence that neural tissue is especially vulnerable to oxidative stress, which plays 
an important role in AD [38].  Neurons are especially vulnerable to ROS-induced damage due to 
high O2 consumption. Brain processes 20% of basal O2 consumption of which 1-2% are converted 
to ROS under physiological conditions [41]. Moreover, ROS levels are even higher when 
mitochondria are damaged. Persistent oxidative stress decreases the level and activity of 26S 
proteasomes with a concomitant increase in the level of 20S proteasomes. The degradation process 
that is mediated by 20S proteasomes is ubiquitin/ATP-independent and may act as a cellular 
strategy to conform to oxidative stress, but the mechanism that leads to the switch from 26S to 20S 
is unknown. Another deleterious mechanism associated with mitochondrial dysfunction is the 
limitation in ATP production that can cause an energy crisis in neurons [137]. Degradation of 
proteins by the 26S proteasome is highly dependent on ATP binding and hydrolysis [112]. Both 
deleterious consequences of mitochondrial impairment, i.e. restricted ATP generating capacity and 
ROS production, impair proteasome-dependent proteolysis in neurons and contribute to 
neurodegeneration. It is clear that there is a mutual dependence between the UPP and mitochondria 
[119], but the specific mechanisms underlying the functional link between UPP and mitochondria 
impairment (Fig. 4) leading to neurodegeneration in AD have not been addressed. New discoveries 
in the functional links between the UPP and mitochondrial impairment and their roles in overall 






1.5. ENDOGENOUS PRODUCT OF INFLAMMATION: PROSTAGLANDIN J2 (PGJ2) 
Prostaglandins of the J2 series are derived 
from PGD2 (Fig.5 adapted from [190]), the principle 
cyclooxygenase product synthesized in the 
mammalian central nervous system (CNS). PGD2 
readily undergoes in vivo and in vitro non-enzymatic 
dehydration to generate PGJ2, which is converted to 
12-PGJ2 and 15-deoxy-12,14-PGJ2 (15d-PGJ2) 
[183]. Unlike most other classes of prostaglandins, 
cyclopentenone PGs like PGJ2 have a 
cyclopentenone ring with reactive ,-unsaturated carbonyl groups (red asterisks, left scheme). 
These highly reactive carbonyl groups form covalent Michael adducts with nucleophiles such as 
free sulfhydryls in cysteine residues of glutathione and cellular proteins [183]. In neuronal cells 
prostaglandins of the J2 series induce apoptosis [43,57,129], inhibit mitochondrial activity 
[95,122,181] as well  as 26S proteasome activity [198], and trigger accumulation and aggregation 
of ubiquitinated proteins [107]. The chemical properties of prostaglandins of the J2 series and their 
pro-oxidant and UPP disrupting effects render them extremely neurotoxic and capable of inducing 
neuronal cell death [190].  
Our studies focus on PGJ2 because it is an endogenous product of inflammation that causes 
pleiotropic changes that mimic many of the pathological processes that occur in neurodegenerative 
disorders that are associated with inflammation, such as AD and Parkinson’s disease (PD).  It has 
been suggested that “formation of cyclopentenone eicosanoids [such as PGJ2] in the brain may 
represent a novel pathogenic mechanism that contributes to many neurodegenerative conditions” 




[131]. Moreover, PGJ2 up-regulates the expression and activity of cyclooxygenase-2 (COX-2), a 
prostaglandin synthesizing enzyme. PGJ2 thus has potential to initiate a series of deleterious 
cascades leading to self-sustained progressive neurodegeneration. Cyclooxygenases are key 
players in inflammation and they mediate the conversion of arachidonic acid into an assortment of 
products. Arachidonic signaling through the cyclooxygenase pathway yields an enormous variety 
of products, some of them with pro-survival, others with pro-death effects. For instance, 
prostaglandins are known to be pro-inflammatory under certain conditions and anti-inflammatory 
under others [reviewed in [201]]. The dual role of prostaglandins is quite complex as a single 
prostaglandin can bind to multiple receptors. For example, two receptors (DP1 and DP2) were 
identified for PGD2 the most abundant prostaglandin in the CNS. DP1 activation increases cAMP, 
activates protein kinase A and is linked to an anti-inflammatory response, while DP2 activation 
increases the cellular influx of calcium and triggers a pro-inflammatory response [reviewed in 
[163]]. PGD2-mediated activation of DP1 was found to be neuroprotective while DP2 activation 
was neurotoxic [109]. Besides binding to different receptors some prostaglandins, such as PGD2, 
are spontaneously metabolized by non-enzymatic dehydration to cyclopentenone prostaglandins, 
such as PGJ2. Cyclopentenone prostaglandins may have an anti-inflammatory effect by inhibiting 
the NFB pathway or a neurotoxic effect by inducing apoptosis [reviewed in [131]]. In our 
laboratory we use PGJ2 to induce pathological events relevant to AD in in vitro as well as in vivo 
studies. PGJ2 causes proteasome impairment, increases the levels of ubiquinated proteins, caspase-
3 activation, caspase-3-dependent Tau cleavage at Asp421 that leads to formation of aggregation-
prone ∆Tau, and formation of ubiquitin aggregates in rat E18 cerebral cortical neurons. PGJ2 also 
induces loss of dopaminergic neurons in SNpc when injected into mouse brain in a PD mouse 




1.6. NEUROPROTECTION BY PACAP27-INDUCED cAMP SIGNALLING PATHWAY 
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the 
VIP/secretin/glucagon/ hormone superfamily that was first isolated from ovine hypothalamic 
extracts on the basis of its ability to stimulate cAMP formation in anterior pituitary cells [125]. 
PACAP is widely distributed throughout the body [191] and has been shown to regulate important 
biological functions, like control of neurotransmitter release, vasodilation, activation of intestinal 
motility, increase in insulin and histamine secretion, stimulation of cell proliferation [191]. 
PACAP is also expressed in the CNS and is known to exhibit neurotrophic and neuroprotective 
properties [2,13]. PACAP exists in two forms: one contains 38 amino acids (PACAP38), and the 
other one 27 amino acids (PACAP27).  
The action of PACAP is exerted by specific binding to PAC1 as well as to VPAC1 and 
VPAC2 G proteins coupled receptors. Binding to VPAC receptors is less specific as vasoactive 
intestinal peptide (VIP) also binds to them with affinity similar to that of PACAP. PAC1 receptors 
are mainly distributed in the CNS, pituitary and adrenal glands while VPAC receptors are found 
mainly in lungs, liver and urogenital tract [67,175]. PAC1 receptor is a G-protein coupled receptor 
which increases intracellular cAMP levels through adenylate cyclase and activates PKA. It can 
also induce MAP kinase cascades. PACAP and PAC1R expression were mapped to hippocampus, 
cerebral cortex, basal ganglia, and other brain areas affected in neurodegenerative diseases.  
Numerous studies showed that PACAP promotes cell survival in various models of 
neurodegenerative diseases [152,153,187]. For example, in in vitro PD models of 
neurodegeneration induced by incubating cultures with 6-hydroxydopamine [186], MPTP [186] 
or rotenone [196], PACAP enhanced dopamine uptake, increased the number of TH-reactive 




induced by 6-OHDA [153] or MPTP [195], PACAP27 treatment rescued neurons in the substantia 
nigra pars compacta. It also increased expression of D2 receptors in striatum and improved 
behavioral deficits. Other beneficial effects against brain damage include neuroprotection in 
middle cerebral artery occlusion (MCAO) by reducing the infarct volume as well as in traumatic 
brain injury (TBI) [17]. PACAP levels were shown to be downregulated along with other 
neurotrophic factors in mouse models of AD which may in part account for increased death of 
neurons [200]. In vitro studies with AD models using Aβ showed that PACAP protects neurons 
against the toxic effects of Aβ by reducing caspase-3 activity and thus apoptosis [141]. PACAP 
also preserved mitochondrial activity and increased alpha-secretase activity. PACAP exerts its 
neuroprotective effect through multiple pathways. It is strongly anti-apoptotic and anti-
inflammatory [31]. It also acts on astrocytes and has anti-oxidant effects. Neurodegenerative 
diseases, like AD, are characterized by proteasome impairment which strongly contributes to 
neuropathological symptoms. Therefore means to increase proteasome activity would be useful as 
potential therapeutic approaches. PACAP provides for such approach, through activation of the 
cAMP-signaling pathway. Elevating cAMP levels has neuroprotective properties via preventing 
caspase-3 activation in an in vitro model of AD [124] but also exerts positive effects on the UPP 
pathway. cAMP activates PKA which in turn phosphorylates Rpt6, a subunit of the 19S regulatory 
particles that contributes to 26S proteasome stability [35]. cAMP/PKA signaling thus increases 
26S proteasome activity and also elevates the expression of proteasome subunits RPt6 and to a 
lesser extent β5. Our previous in vitro studies demonstrated that increasing intracellular levels of 
cAMP via PACAP27 prevented  caspase-3-dependent Tau cleavage at Asp421 leading to  ∆TAU 




in vitro and in vivo data support the notion that elevating cAMP via PACAP27 prevents AD-like 


















 Usp14 inhibitor IU1 is neurotoxic and decreases E1~ubiquitin thioester and ubiquitinated-
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Proteasome activity is reportedly downregulated in Alzheimer’s and Parkinson’s diseases, 
thus increasing proteasome activity could be therapeutically beneficial. The proteasome-associated 
deubiquitinase Usp14 disassembles polyubiquitin chains, potentially delaying proteasome-
dependent protein degradation. We assessed the protective efficacy of inhibiting or 
downregulating Usp14 in rat and mouse (Usp14axJ) neuronal cultures treated with prostaglandin 
J2 (PGJ2). The product of inflammation PGJ2 is neurotoxic and induces accumulation and 
aggregation of ubiquitinated (Ub)-proteins. We established that: inhibiting Usp14 with high IU1 
concentrations (HIU1, >25 µM) reduces the accumulation of Ub-proteins induced by PGJ2, while 
low IU1 concentrations (LIU1, ≤25 µM) have no impact; HIU1 alone or with PGJ2 is neurotoxic, 
and induces calpain-dependent cleavage of Tau, caspase and spectrin; HIU1 decreases E1~Ub 
thioester formation and 26S proteasome assembly, which are energy-dependent processes. We 
attribute the two latter HIU1 effects to ATP-deficits and mitochondrial Complex I inhibition, as 
shown herein. These HIU1 effects mimic those of mitochondrial inhibitors, such as oligomycin. 
Thus, we propose that ATP-depletion is a major mediator of HIU1-actions. Moreover, Usp14 
knockdown by siRNA in rat cultures or loss of Usp14 exhibited in cultures from ataxia (Usp14axJ) 
mice, failed to prevent Ub-protein accumulation induced by PGJ2-treatment. We also show that 
PGJ2 alone induces Ub-protein accumulation and decreases E1~Ub thioester formation. This 
seemingly paradoxical result may be explained by PGJ2 inhibiting deubiquitinases resulting in 
Ub-protein stabilization. In conclusion, we demonstrate that the decline in Ub-protein levels 







 The ubiquitin/proteasome pathway (UPP) and autophagy play a critical role in protein 
quality control and thus have attracted special attention for drug development [39]. Alzheimer’s 
(AD) and Parkinson’s (PD) diseases are of particular interest since a hallmark of these 
neurodegenerative disorders is accumulation/aggregation of Ub-proteins in specific areas of the 
CNS [157]. A potential therapeutic strategy for these disorders could be directed towards 
deubiquitinases to prevent the accumulation and aggregation of Ub-proteins [24].  
 In humans there are around one hundred genes encoding deubiquitinases from five 
different families, four of them being thiol proteases and one a metalloprotease [40]. 
Deubiquitinases perform a range of functions, including processing newly translated ubiquitin 
(Ub) to provide monomers for conjugation and chain formation, trimming mono-Ub from the distal 
end of a poly-Ub chain, disassembling poly-Ub chains, and removing poly-Ub chains from 
substrates [20]. Overall, these functions provide a means for deubiquitinases to regulate “where, 
when and why” ubiquitinated substrates are degraded by the 26S proteasome [157]. 
 The deubiquitinase Usp14 is important for development and functioning of the nervous 
system [23]. Homozygous Usp14 null mice (ataxia mice) exhibit developmental abnormalities 
including motor impairment, reduced brain mass and death by 2 months of age [25]. Usp14 
associates transiently with the proteasome and exhibits Ub-chain trimming activity, thereby 
replenishing the Ub pool [11]. This deubiquitinase can cause premature dissociation of substrates 
from the proteasome, if ubiquitin removal is faster than the competing steps leading to substrate 
degradation [11]. Inhibiting or downregulating Usp14 was proposed as a therapeutic approach for 




of their Ub-chains [101].  
 Selective and reversible inhibition of Usp14 can be achieved with 1-[1-(4-Fluoro-phenyl)-
2,5-dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone, a small molecule known as IU1 [101]. 
Treatment of murine embryonic fibroblasts (MEFs) and human embryonic kidney (HEK)293 cells 
with IU1 resulted in the apparent increased degradation of the proteasome substrates Tau, TDP-43 
and ataxin-3, which have been implicated in neurodegenerative diseases [101]. These studies 
suggest that IU1 or IU1-like drugs could be used therapeutically to prevent the neurotoxic build-
up of such proteins.  
 To test if IU1 prevents accumulation of neuronal Ub-proteins, we treated rat and mouse 
cerebral cortical neurons with the endogenous product of inflammation prostaglandin J2 (PGJ2) 
[47]. PGJ2 is a product of spontaneous dehydration of prostaglandin D2 (PGD2). The latter is the 
most abundant prostaglandin in the brain [71,172,190] and the one that increases the most under 
pathological conditions [109]. In rodents, the in vivo concentration of free PGJ2 in the brain upon 
stroke and traumatic brain injury increases from almost undetectable to the 100 nM range 
[115,116]. These values represent average brain levels. Regional brain concentrations of PGJ2 are 
potentially higher [117], as PGJ2 binds covalently to proteins, and therefore, free PGJ2 does not 
represent its total amount. Unlike most prostaglandins, PGJ2 and its metabolites have a 
cyclopentenone ring with reactive ,-unsaturated carbonyl groups. These carbonyl groups form 
covalent Michael adducts with cysteine thiols of glutathione or cellular proteins [183]. 
Electrophiles, such as PGJ2, that bind to specific protein cysteine(s) are regarded to play an 
important role in determining neuronal survival [162]. 




in neuronal cells, including PGA1, D2, E2 and J2 [108]. In addition, PGJ2 impairs the UPP by 
targeting different components of this pathway including the 26S proteasome by perturbing its 
assembly [139,198], deubiquitinases such as UCH-L1 and Ub isopeptidase activities 
[93,108,115,130], and by causing the accumulation/aggregation of Ub-proteins [108,116]. Besides 
its effects on the UPP, we showed that PGJ2 activates caspases and caspase-mediated proteolysis 
in primary cerebral cortical neuronal cultures, leading to Tau cleavage and pathology [3,124]. In 
sum, PGJ2 induces a range of pathological processes relevant to neurodegenerative disorders [47].  
 In the current study we demonstrate that inhibition of Usp14 with high concentrations of 
IU1 (HIU1, >25 µM) prevents/reduces the accumulation of Ub-proteins in rat cerebral cortical 
neuronal cultures treated with PGJ2. This effect of HIU1 can be attributed in part to a decline in 
E1-dependent ubiquitin activation, as we show that IU1 lowers E1~Ub thioester levels. The latter 
is consistent with the observed drop in ATP levels and mitochondrial Complex I activity induced 
by HIU1. HIU1 was also neurotoxic and induced calpain-dependent cleavage of Tau, spectrin and 
caspase. Overall, the effects of HIU1 on neuronal Ub-protein levels, E1- and calpain-activities, Tau 
cleavage and ATP levels, mimic those of mitochondrial inhibitors, such as oligomycin [78]. Lower 
IU1 concentrations (LIU1, 25 µM), or downregulating Usp14 by siRNA, or loss of Usp14 
(Usp14axJ mouse) had no impact on Ub-protein levels.  We also established that PGJ2 lowers 
E1~Ub thioester levels without directly inhibiting E1 activity.  In contrast to IU1, PGJ2 promotes 
the accumulation of Ub-proteins in neuronal cultures. In conclusion, a deeper understanding of the 
mechanisms that regulate Ub-protein accumulation, including the balance among E1, 
deubiquitinase and proteasome activities, is critical for drug development that aims at reducing the 





2.3. MATERIALS AND METHODS 
2.3.1. Materials: Chemicals: IU1 (Life Sensors, Malvern, PA); calpeptin (Calbiochem/EMD 
Bioscience, Gibbstown, NJ); proteasome substrate Suc-LLVY-AMC (BACHEM Bioscience Inc., 
King of Prussia, PA); PGJ2 (Cayman Chemical, Ann Arbor, MI); oxidative phosphorylation 
substrates, creatine phosphokinase, and bovine ubiquitin (Sigma-Aldrich, St. Louis, MO). Primary 
antibodies: chicken polyclonal anti-Usp14 (1:1,000, cat# AB505) from Life Sensors, Malvern PA; 
rabbit polyclonal anti-ubiquitinated proteins (1:1,500, cat# Z0458) from Dako North America, 
Carpinteria, CA; rabbit polyclonal anti-β5 (1:5,000, cat# PW8895), and mouse monoclonal anti-
Rpt6 (1:2,000, cat# PW9265), from ENZO Life Sciences, Inc., Farmingdale, NY; mouse 
monoclonal anti-β-actin (1:10,000, cat# A-2228) from Sigma, St. Louis, MO; mouse monoclonal 
anti-spectrin α chain (clone AA6, cat# MAB1622) from Millipore, Billerica, MA; mouse 
monoclonal Tau C3 (1:5,000; detects Tau cleaved at Asp421; ep: a.a. 412–421) and mouse 
monoclonal Tau C5 (1:50,000; detects all Tau isoforms and ΔTau; ep: a.a. 210–241) were courtesy 
of Dr. L. Binder (Northwestern University, Chicago, IL, USA); rabbit polyclonal anti-UBE1a 
(1:1000, cat# 4890) and anti-caspase 3 (1:1000, cat# 9662) from Cell Signaling Technology, 
Danvers, MA. Secondary antibodies with HRP conjugate (1:10,000) from Bio-Rad Laboratories, 
Hercules, CA. 
2.3.2. Mice - C57BL/6J mice (wild type) and Usp14axJ mice maintained on a C57BL/6J 
background (Jackson Laboratories, Bar Harbor, MA) have been maintained in the breeding colony 
at the University of Alabama at Birmingham. Homozygous Usp14axJ mice were generated by 
intercrossing heterozygous axJ siblings. 




cerebral cortical neurons were prepared as in [78]. Dissociated cultures from wild type and 
homozygous Usp14axJ mouse embryos were prepared as in [28]. The isolated cortices free of 
meninges were digested with papain (0.5 mg/ml from Worthington Biochemical Corp.) in 
Hibernate E without calcium (BrainBits LLC.) at 37oC for 30 min in a humidified atmosphere 
containing 5% CO2. After removal of the enzymatic solution, the tissues were gently dissociated 
in Neurobasal media (Invitrogen). Dissociated tissues were centrifuged at 300Xg for 2 min. The 
pellet was resuspended in Neurobasal media without antibiotics and plated on 10 cm dishes pre-
coated with 50 µg/mL poly-D-lysine (Sigma). Cells were plated at a density of 6X106 cells per 10 
cm dish, or 2.5X105 cells per well on 24-well plates (cell viability only). Cultures were maintained 
in Neurobasal media supplemented with 2% B27 and 0.5 mM L-Glutamax (all from Invitrogen) 
at 37°C in a humidified atmosphere containing 5% CO2. Half of the medium was changed every 4 
days. Experiments were run 8-11 DIV. According to manufacturer’s specifications, Neurobasal 
medium contains several proprietary factors that ensure a mostly pure (> 95%) neuronal culture; 
glial growth is inhibited without a need for the anti-mitotic agent arabinofuranosyl cytidine 
[14,135].  
2.3.4. Culture treatments – Cortical neurons were treated acutely (4 h, 8 h, 16 h or 24 h) with 
DMSO or with the different drugs in DMSO added directly to DMEM without serum, 
supplemented with 0.5 mM L-Glutamax and 1 mM sodium pyruvate (all from Invitrogen). The 
final DMSO concentration in the medium was 0.5%.  
2.3.5. Cell viability assay - Cell viability was assessed with the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay as described [128].  




luciferin/luciferase system (Molecular Probes). This assay is based on luciferase requiring ATP 
for light production using luciferin as a substrate. Cells were harvested with 4% trichloroacetic 
acid followed by centrifugation (19,000Xg, 15 min at 4ºC). ATP steady state levels were 
determined in cleared supernatants after neutralizing the samples with 1 M Tris-HCl, pH 8.0. 
Samples were then added to the reaction buffer containing luciferin and assayed using a 
Luminoskan Ascent microplate luminometer (Thermo Electron Corporation). Protein 
concentration was determined with the bicinchoninic acid (BCA) assay kit (Pierce) after 
resuspending the pellet in10 mM Tris-HCl (pH 8.0) and 1% SDS followed by sonication. ATP 
levels were normalized to protein concentration determined with the BCA assay. 
2.3.7. Mitochondrial respiratory chain complex activities - Bovine heart submitochondrial 
particles (SMP) were prepared according to standard procedures [53]  and stored in liquid nitrogen. 
Before activity measurements, SMP were resuspended to 5 mg/ml in SET buffer pH 7.5 (0.25 M 
sucrose, 0.2 mM EDTA, 50 mM Tris-HCl), containing 0.2 mM malonate and incubated at 30°C 
for 30 min. NADH-dependent enzymatic activities of Complex I were assayed 
spectrophotometrically (Perkin Elmer Lambda 35) as a decrease in absorption at 340 nm (ε340 nm 
= 6.22 mM-1 cm-1) with 150 μM NADH in SET buffer containing 2.5–25 μg of protein/ml SMP. 
For the measurements of NADH:Q1 or NADH:HAR oxidoreductase activity, SMP were assayed 
in the presence of 1 mM cyanide with the addition of 80 μM Q1 or 1 mM HAR, respectively. The 
Complex IV activity was measured at 550 nm (ε550nm = 21.5 mM-1 cm-1) with 45 µM 
ferrocytochrome c in two fold  diluted SET buffer containing 0.025% laurilmaltoside and 2.5-5 μg 
of protein/ml SMP. Since IU1 strongly absorbs in the near UV region, succinate oxidase activity 
was measured as oxygen consumption using Oroboros oxygraph in SET buffer containing 5 mM 




enzymes, SMP were preincubated directly in the measuring medium for 2 min with the inhibitor 
before initiating the reaction with a substrate. Separate control studies confirmed the preincubation 
time was sufficient to reach equilibrium in the enzyme-inhibitor reaction. All activities were 
measured at 30°C and expressed in µmol of substratemin-1mg-1. Protein concentration was 
determined with the BCA assay. Reported values are the mean ± SD (at least 3 independent 
experiments). 
2.3.8. Western blotting - After treatment, cells were rinsed twice with PBS and harvested by 
gently scraping into ice-cold lysis buffer [20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 1 mM EGTA, 
2.5 mM Na4P2O7, 1 mM β-glycerophosphate, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 
1% NP40, 1 mM Na3VO4, 1% Glycerol and protease inhibitor cocktail (Sigma-Aldrich, St Louis, 
MO)]. Following lysis (at least 30 min, -80oC), cell extracts were centrifuged (19,000xg for 10 
min) at 4oC. Protein concentration of the NP40-soluble supernatants was determined with the BCA 
assay. Western blot analysis was carried out following SDS-PAGE. Normalized samples were 
boiled for 5 min in Laemmli buffer and loaded onto gels (30 µg of protein/lane). Following 
electrophoresis, proteins were transferred onto an Immobilon-P membrane (Millipore, Bedford, 
MA, USA). The membrane was probed with the respective antibodies, and antigens were 
visualized by a standard chemiluminescent horseradish peroxidase method with the ECL reagent. 
Semi-quantitative analysis of protein detection was done by densitometry including image analysis 
with the ImageJ program (Rasband, W.S., ImageJ, U.S. NIH, Maryland, http://rsb.info.nih.gov/ij/, 
1997-2006). 
2.3.9. Evaluation of endogenous E1~ubiquitin thioester – Upon treatment with vehicle (control, 
DMSO) or with the respective drugs, cortical neurons were washed once with PBS, harvested with 




ethylmaleimide, 3 mM EDTA, 2% protease inhibitor cocktail (Sigma)], and kept on ice for 15 min 
for lysing, as described [85]. Samples were sonicated for 10 s, centrifuged at 19,000Xg for 15 min 
at 4oC, mixed (30 μg) 1:2 (volume) with thioester gel buffer (33 mM Tris-HCl, pH 6.8, 2.7 M urea, 
2.5% SDS and 13% glycerol), and boiled for 5 min. After determination of the protein 
concentration with the Bradford assay (Bio-Rad Laboratories), the normalized samples were 
separated into reducing (with 4% -mercaptoethanol) and non-reducing (no -mercaptoethanol) 
aliquots for SDS-PAGE, followed by western blotting with anti-E1 antibody, as described above. 
2.3.10. In vitro E1 activity assay– Commercial bovine ubiquitin was further purified to apparent 
homogeneity by FPLC and quantified spectrophotometrically [5].  Ubiquitin was radioiodinated 
by the Chloramine-T procedure using carrier-free Na125I to yield a specific radioactivity of 
∼20,000 cpm/pmol [64].  Human Uba1 was purified to apparent homogeneity from outdated 
erythrocytes and active Uba1 was determined by the stoichiometric formation of 125I-ubiquitin 
thioester [64].  One pmol of Uba1 was pre-incubated with 0.5% DMSO (vehicle) or 15 μM PGJ2 
(0.5% DMSO) at 4°C in 50 mM Tris-HCl (pH 7.5) for 0, 1, 2, 4, 6, 12, and 24 hours.  Formation 
of E1 thioester was analyzed at 37°C in 25 μl reactions containing 50 mM Tris-HCl (pH7.5), 1 
mM ATP, 10 mM MgCl2, 10 mM creatine phosphate, 1 IU of creatine phosphokinase and an 
aliquot of the time point equivalent to 40 nM Uba1 (original content).  Reactions were started by 
the addition of 4 μM 125I-ubiquitin and quenched after 1 min by the addition of 25 μl 2X SDS 
sample buffer.  The E1~125I-ubiquitin thioesters were resolved from free 125I-ubiquitin by 12% 
SDS-PAGE under non-reducing conditions at 4°C and visualized by autoradiography. Where 
indicated, E1 was quantified by excising the E1~125I-ubiquitin thioester band, quantifying 
associated radioactivity by gamma counting, and calculating absolute thioester formation using 




2.3.11. In gel proteasome activity and levels – Upon treatment with vehicle (control, DMSO) or 
the respective drugs, cells were washed twice with PBS and harvested for the in gel assay as 
described in [132]. The native gels loaded with 30 µg protein/lane, were run at 150 V for 120 min. 
The in gel proteasome activity was detected by incubating the native gel on a rocker for 10 min at 
37oC with 15 ml of 300 μM Suc-LLVY-AMC followed by exposure to UV light (360 nm). Gels 
were photographed with a NIKON Cool Pix 8700 camera with a 3-4219 fluorescent green filter 
(Peca Products, Inc). Proteins on the native gels were transferred (110 mA) for 2 h onto PVDF 
membranes. Immunoblotting was carried-out for detection of the 20S and 26S proteasomes with 
the anti-Rpt6 and anti-β5 antibodies, which react with subunits of the 19S or the 20S particles, 
respectively. Antigens were visualized by a chemiluminescent horseradish peroxidase method 
with the ECL reagent.  
2.3.12. Caspase-3 and calpain activation - Cell lysates were analyzed by standard western 
blotting with the anti-caspase-3 antibody to detect caspase-3 cleavage that is indicative of 
apoptosis. Calpain activation was assessed with the anti-α-spectrin antibody. Calpain cleavage of 
α-spectrin generates a 150/145 kDa doublet, while caspase cleavage generates a 120 kDa fragment 
[197]. 
2.3.13. siRNA – The dicer siRNA substrates targeting the Usp14 gene obtained from IDT 
(Coralville, Iowa), were encapsulated into lipid nanoparticles using microfluidic technology by 
Precision NanoSystems (SUB9KITSTM; Vancouver, Canada). Cells were treated with 0.1 µg/ml 
of Neuro9TM RNAi nanoparticles as described in [161] for 72 h prior to treatment with 10 µM 
PGJ2 for 16 h. During siRNA treatment, cells remained in Neurobasal media supplemented with 
2% B27 and 0.5 mM L-Glutamax (all from Invitrogen) at 37°C in a humidified atmosphere 




to DMEM without serum, supplemented with 0.5 mM L-Glutamax and 1 mM sodium pyruvate 
(all from Invitrogen) and cells were treated with 10 µM PGJ2 for 16h. 
2.3.14. Statistical analysis - Statistical significance was estimated using one-way ANOVA 
(Tukey-Kramer multiple comparison test) or the Welch's t-test (two group comparison) with the 
Prism 6 program (GraphPad Software, San Diego, CA).  
2.4. RESULTS 
2.4.1. IU1 blocks PGJ2-induced accumulation of ubiquitinated proteins and triggers calpain-
mediated cleavage of Tau, caspase 3 and spectrin – Since IU1 was proposed to promote protein 
degradation by the proteasome [101] we examined its effects on neuronal Ub-protein levels. IU1 
was not previously tested on neurons [101]. To increase the endogenous levels of Ub-proteins, the 
rat cerebral cortical neuronal cultures were treated with the product of inflammation PGJ2 
[174,190]. The neurons were pre-incubated with IU1 (75 µM) for 6 h prior to PGJ2 treatment (15 
µM, 16 h). A similar protocol was used to establish protection by IU1 against proteotoxic stress in 
HEK293 cells treated with menadione, an oxidative stressor [101]. As expected, PGJ2 significantly 
increased the levels of Ub-proteins but IU1 by itself did not (Fig. 6, lanes 2 and 3, panels 1 and 
2). In addition, IU1 blocked the accumulation of Ub-proteins induced by PGJ2 (Fig. 6, compare 
lanes 2 and 4, panels 1 and 2).  Compared to control conditions (lane 1) the levels of free Ub were 






IU1 was previously shown to promote the degradation of a Tau isoform overexpressed in 
wild type MEFs [101]. Tau is a microtubule associated protein that is abundant in neurons and 
Figure 6. IU1 blocks PGJ2-induced 
accumulation of ubiquitinated 
proteins and triggers calpain-
mediated cleavage of Tau, caspase 3 
and spectrin 
 NP-40 soluble fractions from rat E18 
cerebral cortical neurons treated as 
indicated were analyzed by western 
blotting (30 μg of protein/lane) and 
probed with the respective antibodies 
to assess the effect of the treatments 
on: level of ubiquitinated proteins 
(panel 1 and 2), Tau FL (full-length) 
and other Tau fragments (panel 3), Tau 
cleaved at Asp412, Tau (panel 4), 
caspase 3 (panel 5),  α-spectrin (panel 
6),     actin as loading control (panel 7). 
Molecular mass markers in kDa are 




highly soluble, yet Tau forms abnormal aggregates and is the major component of neurofibrillary 
tangles, one of the hallmarks in AD [121]. Confirming what we previously demonstrated [124], 
PGJ2 induced caspase-mediated cleavage of Tau (Tau, Fig. 6, panel 4, lane 2). Tau is prone to 
aggregation and its formation is an early event in AD tangle pathology [29,54,156]. In contrast to 
PGJ2, IU1 induced calpain-mediated cleavage of Tau (Fig. 6, panel 3, lane 3), reminiscent of what 
we observed in cortical neurons treated with the mitochondrial inhibitor oligomycin [78]. IU1 
combined with PGJ2 further increased calpain-mediated cleavage of Tau (Fig. 6, panel 3, lane 4).  
 We established that IU1-treatment induces calpain activation, while PGJ2-treatment 
triggered mostly caspase 3 activation. As shown in Fig. 6 (panel 5, lane 3), IU1 triggered the 
cleavage of pro-caspase 3 to a ~29 kDa inactive fragment [143] (Cl-caspase 3) and not to its active 
17 kDa form (Act-caspase 3). On the other hand, PGJ2 induced the cleavage of pro-caspase 3 (33 
kDa) to its active form (17 kDa, Act-caspase 3, Fig. 6, panel 5, lane 2), as we previously showed 
[3]. We further confirmed that calpain was activated upon IU1-treatment by assessing cleavage of 
-spectrin, a calpain substrate. IU1-treatment by itself or in combination with PGJ2 clearly 
induced cleavage of -spectrin (Pro--spectrin, 280 kDa) to 145/150 kDa fragments [Cl--
spectrin (150)], which are indicative of calpain activation (Fig. 6, panel 6, lanes 3 and 4). In 
contrast, PGJ2-treatment mostly induced -spectrin cleavage to a 120 kDa -spectrin fragment 
[Cl--spectrin (120)], which is a marker of apoptotic cell death [197]. Furthermore, pre-treatment 
with the calpain inhibitor calpeptin (Z-Leu-norleucinal) prevented calpain-dependent Tau and 
spectrin cleavages induced by IU1 alone (Fig. 6, panels 3 and 6, compare lanes 3 and 6). In 
contrast, treatment with both calpeptin and IU1 stimulated caspase-dependent Tau cleavage the 





 We next addressed if lower IU1 concentrations (25 µM) also blocked the accumulation of 
Ub-proteins induced by PGJ2. For these experiments we reduced the PGJ2 concentration to 10 
µM, as we also lowered IU1 levels. Adding IU1 to the neuronal cultures prior to PGJ2-treatment 
had the same effect as co-incubation with the two drugs (not shown). Therefore, in all subsequent 
experiments both agents were added at the same time. Although in some experiments IU1 at a 25 
µM  appeared to decrease the levels of Ub-conjugates induced by 4 h (Fig. 7A and 7C), or 24h 
PGJ2-treatment, this effect was not statistically significant(Fig. 7B and 7C). 





Figure 7. Low concentration of IU1 (≤25 µM) did not affect the accumulation of Ub-proteins induced by 
PGJ2. NP-40 soluble fractions from rat E18 cerebral cortical neurons treated as indicated were analyzed by 
western blotting (30 μg of protein/lane) and probed with the respective antibodies to assess the effect of the 
treatments on the level of ubiquitinated proteins (A and B) using actin as loading control. Quantification (C). 
Molecular mass markers in kDa are shown. In C the levels of ubiquitinated proteins (polyUb/actin) were semi-
quantified by densitometry. Data represent the percentage of the pixel ratio for Ub-proteins over the respective 




2.4.2. IU1 reduces cell viability and depletes intracellular ATP levels – Calpain-activation is 
linked to ATP-depletion and necrosis, a cell death pathway associated with a bioenergetic crisis 
[209]. In fact, calpain-activation was shown to be induced by inhibitors of oxidative 
phosphorylation, such as rotenone, antimycin and oligomycin [173]. As we established that IU1 
induces calpain activation, we reasoned that IU1 may be neurotoxic and lower intracellular ATP 
levels. 
 
 As shown in Fig. 8, IU1 caused a decline in cell viability in a concentration (panel A) and 
time-dependent-manner (panel B), the latter assessed for 25 µM. In addition, treatment with PGJ2 
(10 µM) and IU1 (25 µM) combined was even more neurotoxic than any of the drugs alone (panel 
Figure 8. IU1 reduces neuronal viability 
Neurons were treated with indicated 
concentrations of IU1 and/or 10µM PGJ2. 
Cell viability was assessed with the MTT 
assay. Percentages represent the ratio 
between the data for each condition and 
control (100%). Values indicate means and 
s.e.m. from at least three experiments per 
group. Asterisks identify values that are 
significantly different from control (* 




C). The loss of neuronal viability was assessed with the MTT assay, which is reduced largely 
within the cytoplasm [10,118].  
 As we predicted, IU1 decreased ATP levels also in a concentration (Fig. 9A) and time 
dependent manner (Fig. 9B). Moreover, treatment with PGJ2 (10 µM) combined with IU1 (25 
µM) decreased ATP levels the most, compared to the effectiveness of either compound alone 
(panel C).  
 The decline in ATP levels induced by the 24h treatment with 25 µM IU1 varied between 
70% (Fig. 9B) and 90% (Fig. 9A) of control. The loss of cell viability under the same conditions 
fluctuated between 40% (Fig. 8 A and B) and 80% (Fig. 8C) of control. This variation could reflect 
somewhat the heterogeneity of the primary neuronal cultures for each experiment that are prepared 
from a different set of rat embryos. The finding that neurons that exhibit a 70% to 90% loss of 
ATP still exhibit low levels of viability is in line with other studies. For example, we showed that 
30% of oligomycin-treated rat cortical neurons exhibiting a loss of ~78% of their ATP where still 
viable [78]. In our studies, the neurons in culture are post-mitotic and not engaged in synaptic 






2.4.3. IU1 inhibits mitochondrial Complex I - (These studies were carried-out by Alexander 
Galkin, School of Biological Sciences, Queen's University Belfast, Belfast, BT9 7BL, United 
Kingdom, Feil Family Brain and Mind Research Institute,  Weill Cornell Medical College, New 
York, NY 10065, USA; Anna Stepanova, N.K. Koltzov Institute of Developmental Biology, Russian 
Academy of Sciences, Moscow 119334, Russia). As shown in Fig. 10, NADH-oxidase (A) and 
NADH:Q1 reductase (B) activities of Complex I were inhibited by IU1, the latter with an IC50 of 
around 40 µM. This indicates a direct effect of IU1 on physiological oxidation of NADH by 
ubiquinone in mitochondrial Complex I. At a much higher concentration IU1 also inhibited 
oxidation of NADH by the artificial acceptor hexaammineruthenium (HAR, C). In addition, at this 
concentration range IU1 had almost no effect on succinate-oxidase (Complex II-IV, D) or on 
cytochrome c oxidase alone (Complex IV, E).   
Figure 9. IU1 depletes intraneuronal ATP 
levels. Neurons were treated at indicated 
time points with 25µM IU1 and/or 10µM 
PGJ2. ATP steady state levels (pmoles/μg of 
protein) were assessed with the 
luciferin/luciferase system. Values depict 
the mean and s.e.m. from at least three 
determinations. Asterisks identify values 




2.4.4. IU1-induced decline in Ub-protein accumulation correlates with E1 failure - To address 
a mechanism mediating the IU1-induced decline in Ub-protein accumulation, we focused on the 
E1 ubiquitin activating enzyme. E1 activity requires ATP for formation of a thioester adduct with 
ubiquitin. In principle, if E1 activity is impaired, protein ubiquitination should be diminished. To 
assess E1~Ub thioester levels, which are sensitive to reducing agents, the samples were run on 
SDS-PAGE under reducing (with β-mercaptoethanol) and non-reducing (without β-
mercaptoethanol) conditions. As shown in Fig. 11A (panel 1), in the control sample under non-
reducing conditions E1~Ub thioester (~126 kDa) migrated ~9 kDa above native E1 (117 kDa), 
Figure 10. IU1 inhibits mitochondrial Complex 
I. Mitochondrial respiratory chain complex 
activities were measured in bovine heart 
submitochondrial particles (SMP) using various 
concentrations of IU1 as described in ‘Materials and 
Methods’ section. Reported values are the mean 




consistent with the additional mass of ubiquitin. PGJ2 (15 µM) or HIU1 (50 µM)-treatment 
abolished the E1~Ub thioester, reflecting the loss of the ubiquitin monomer linked to E1 (Fig. 11A, 
panel 1). The effect of lower IU1 concentrations (≤25 µM) alone on E1~Ub thioester was minimal. 
As expected, when PGJ2 was combined with increasing concentrations of IU1 (Fig. 11A, panel 
1), the E1~Ub thioester was almost undetectable.   
 
 Under reducing conditions (Fig. 11A, panel 2) only native E1 was detected in all treatments. 
PGJ2 combined with 50 µM IU1, decreased the levels of E1~Ub thioester and native E1. As shown 
Figure 11 A.  IU1-induced decline in Ub-protein accumulation correlates with E1 failure NP-40 
soluble fractions from rat E18 cerebral cortical neurons treated as indicated were analyzed by western 
blotting (30 µg of protein/lane) probed with the respective antibodies to detect E1-Ub (ubiquitin) thiol 
esters and native E1, run under non-reducing conditions (panel 1), or reducing conditions with β-
mercaptoethanol (panel 2); Ub-proteins (panel 3); actin (loading control). Quantification of total E1 levels 




on the graphs on the right, total E1 levels (E1~Ub thioester + native E1) assessed under reducing 
conditions were not altered significantly (p>0.05), except in the PGJ2 plus IU1 (50 µM) treatment 
(p = 0.0014, quantification shown in the graphs on the right). These data demonstrate that in 
neurons HIU1-mediated ATP depletion prevents E1 from forming thioester intermediates with 
ubiquitin. The latter correlates with a major down-regulation of Ub-proteins in PGJ2-treated 
neurons (Fig. 11A panel 3). Unconjugated (free) ubiquitin and actin levels (Fig. 11A, panels 3 and 
4, respectively) were not decreased by IU1. 
2.4.5. PGJ2 induces a time-dependent decline in E1~Ub thioester formation while raising the 
levels of Ub-proteins – We characterized the temporal effect of PGJ2 on E1~Ub thioester 
formation and compared it with the accumulation of Ub-proteins in the rat neurons. As shown in 
Fig. 11B (panel 1), 15 µM PGJ2 prevented E1~Ub thioester formation by 8 h of treatment. 
Moreover, PGJ2 increased the accumulation of Ub-proteins by 8 h of incubation (Fig. 11B, panel 
3), despite the absence of E1~Ub thioester formation (Fig. 11B, panel 1). This seemingly 
paradoxical result is addressed below in the discussion.  
   To determine if the PGJ2-dependent ablation of cellular E1~Ub formation was a direct 
effect, such as from covalent adduct formation at the active site cysteine of the activating enzyme, 
a biochemically-defined assay for E1 thioester formation in the absence or presence of PGJ2 was 
conducted (Fig. 11C).  Human E1 is relatively stable in the presence of DMSO alone or in the 
presence of 15 μM PGJ2 in DMSO for up to 24 hours (Fig. 11C).  These studies (Fig. 11C) were 
carried-out by Arthur Haas and Dustin R. Todaro, Department of Biochemistry and Molecular 










  Figure 11 B, C. PGJ2 induces a time-dependent decline in E1~Ub thioester formation while raising 
the levels of Ub-proteins. (B) NP-40 soluble fractions from rat E18 cerebral cortical neurons treated as 
indicated were analyzed by western blotting (30 µg of protein/lane) probed with the respective antibodies 
to detect E1-Ub (ubiquitin) thiol esters and native E1, run under non-reducing conditions (panel 1), or 
reducing conditions with β-mercaptoethanol (panels 2); Ub-proteins (panel 3); actin (loading control). (C) 




2.4.6. HIU1 induces a decline in 26S proteasomes and a concomitant increase in 20S 
proteasomes –The activity and assembly/disassembly of 26S proteasomes are highly dependent 
on ATP binding and hydrolysis [44,114]. We thus assessed with the native in-gel assay, the effects 
of IU1 on proteasome activity and levels in the cortical neurons. The in-gel assay detects the three 
assembled forms of the proteasome: 26S proteasomes with either two regulatory caps [26S(2)] or 
one cap [26S(1)], and the 20S core particle alone (20S). Proteasome activity was determined with 
the substrate Suc-LLVY-AMC, which assesses the chymotrypsin-like activity (Fig. 12). Under 
control conditions (lanes marked with “0”), the activity of the 20S proteasome is substantially 
lower than that of the 26S, because the 20S is a latent proteasome form [60]. Proteasome levels 
were determined by immunoblotting with the anti-Rpt6 antibody that reacts with an ATPase 
subunit of the 19S particle (Fig. 12, panel 3), and with the anti-β5 antibody (Fig. 12, panel 4). The 
β5 subunit is a component of the 20S core, thus its antibody detects assembled 26S and 20S 
proteasomes. It is clear that HIU1 induced a decline in 26S proteasome activity that correlates with 
lower ATP levels [compare Fig 9A for ATP with Fig. 12 (panel 1) for 26S proteasome activity]. 
Furthermore, HIU1 blocked 26S assembly (or promoted disassembly), as its activity and levels 
decreased while those of the 20S proteasome increased (Fig. 12, panels 1 and 2 for activity and 
panels 3 and 4 for levels). PGJ2-mediated inhibition of the 26S proteasome is shown for 










Figure 12. HIU1 induces a decline in 26S proteasomes and a concomitant increase in 20S proteasomes Neurons 
were treated for 24h with 10µM PGJ2 or various concentrations of IU1 (A). Lysates (30µg/sample) were subjected to 
non-denaturing gel electrophoresis as described under “Experimental Procedures”. Fully assembled 26S and 20S 
proteasomal (indicated in the middle by arrows) chymotrypsin-like activity was assessed with Suc-LLVY-AMC by 
the in-gel assay (panels 1 and 2).  To improve detection of 20S proteasome activity, 0.04% SDS was added to the 
reaction buffer in panel 2. Proteasome levels were detected by immunoblotting with anti-Rpt6 (panel 3) and anti-β5 
antibodies (panel 4). Proteasome chymotrypsin-like activity and levels were quantified by densitometry (B). 
Percentages represent the ratio between data for each condition and control (DMSO) considered to be 100%. Values 
are means from at least three experiments. Asterisks identify values that are significantly different from control 




2.4.7. Usp14 knockdown by siRNA or Usp14 loss (Usp14axJ  mouse) did not prevent the 
deleterious effects of PGJ2 – To determine if lowering Usp14 levels counteracts some of the 
PGJ2 effects on the neurons, we induced Usp14 knock down by siRNA prior to treatment with 
vehicle (control) or PGJ2 (Fig. 13B, panel 1). Usp14 siRNA had no clear impact on the PGJ2-
induced changes on neuronal viability (Fig. 13A), ΔTau, the caspase-dependent Tau fragment (Fig. 
13B, panel 2), activated caspase 3 (Fig. 13B, panel 3), or ubiquitinated proteins (Fig. 13B, panel 
4).  
  Likewise, studies with cortical cultures from Usp14axJ mice which exhibit a 90-95% loss 
of Usp14 (Fig 13C, panel 1), show that Usp14 depletion has no benefit against the deleterious 
effects of PGJ2 tested, i.e. caspase-activation, and accumulation of Ub-proteins (Fig.13C, panels 
2 to3, respectively). These studies (Fig. 13C) were carried-out by Scott M. Wilson, Department of 
Neurobiology, Civitan International Research Center, University of Alabama at Birmingham, 





Figure 13 A. Usp14 siRNA had no clear impact on the PGJ2-induced changes on neuronal viability. Neurons 
were treated with indicated concentrations of IU1 and/or 10µM PGJ2. Cell viability was assessed with the MTT 
assay. Percentages represent the ratio between the data for each condition and control (100%). Values indicate 
means and s.e.m. from at least three experiments per group. Asterisks identify values that are significantly different 





Figure 13 B. Usp14 knockdown by siRNA did not prevent the deleterious effects of PGJ2 Neurons 
were treated with 0.1 µg/ml of Neuro9TM RNAi nanoparticles targeting Usp14 gene as described in 
‘Materials and Methods’ section. Cell viability was assessed with the MTT assay (A). Percentages 
represent the ratio between the data for each condition and control (100%). Values indicate means and 
s.e.m. from at least three experiments per group.NP-40 soluble fractions from rat E18 cerebral cortical 
neurons treated as indicated were analyzed by western blotting (20 μg of protein/lane) (B) and probed 
with the respective antibodies to assess the effect of the treatments on: Usp14 (panel 1), Tau cleaved at 
Asp412, Tau (panel 2), caspase 3 (panel 3), level of ubiquitinated proteins (panel 4) and actin as loading 

























Figure 13C. Usp14 loss (Usp14axJ mouse) did not prevent the deleterious effects of PGJ2.  Dissociated 
cultures from homozygous Usp14axJ mice prepared as in [24] were treated as indicated. Loss of Usp14 in 









  In this study we characterize the mechanism(s) by which the Usp14 inhibitor IU1 affects 
the ubiquitin/proteasome pathway (UPP) in rat cerebral cortical neurons. In non-neuronal cells, 
IU1 is proposed to enhance the degradation of a range of proteasome substrates including Tau and 
oxidized proteins [101], which are implicated in neurodegenerative disorders such as AD and PD. 
Thus, it was critical to investigate the impact of IU1 on neurons. 
We show that 75 µM IU1 prevented the accumulation of Ub-proteins induced by PGJ2 in 
neurons, while IU1 concentrations 25 µM had no impact. IU1 (75 µM) was shown to reduce 
menadione-induced accumulation of oxidized proteins in non-neuronal HEK293 cells [101]. Like 
PGJ2 [108,115], the vitamin K analog menadione (K3) induces accumulation of Ub-proteins 
[199,205]. However, whether or not IU1 blocks menadione-induced accumulation of Ub-proteins 
was not addressed [101]. This is important, as non-aggregated Ub-proteins are turned over by the 
26S proteasome, the activity of which is enhanced by inhibiting Usp14 with IU1 [101]. On the 
other hand, most (70% to 80%) of all oxidized proteins that are not aggregated are degraded by 
20S proteasomes in concert with immunoproteasomes [147]. The latter forms of the proteasome 
do not associate with Usp14 and are not postulated to be affected by IU1 [101,146]. We discuss 
the impact of IU1 on 20S proteasome activity in neurons below.  
We also demonstrate that 75 µM IU1 induces calpain-dependent cleavage of endogenous 
Tau, as Tau cleavage is blocked by a calpain inhibitor (calpeptin). This is further supported by the 
finding that IU1-treatment clearly induces cleavage of -spectrin (280 kDa) to 145/150 kDa 
fragments, which are indicative of calpain activation [197]. Moreover, the IU1-induced Tau 
fragments include a typical “17 kDa” fragment, which represents a marker for enhanced calpain 




Calpain-activation is linked to ATP-depletion and necrosis, a cell death pathway 
characterized by a bioenergetic crisis [209]. It is well established that calpain-activation is induced 
by mitochondrial inhibitors, such as oligomycin and antimycin [173]. Of relevance, we find that 
the pattern of IU1-induced Tau cleavage in neurons resembles that observed in our previous studies 
with these inhibitors [78]. In a similar manner, IU1 induced calpain-mediated cleavage of caspase 
3 to a fragment (29 kDa) associated with caspase inactivation [78,143]. Calpain processing of 
caspase 3 to the 29 kDa inactive form could be a strategy to prevent execution of the apoptotic 
pathway under conditions of ATP-deficit, as apoptosis is an energy-dependent death pathway 
[209]. Together these data show that IU1 (75 µM) treatment in neurons activates calpain-
dependent cleavage of Tau, spectrin and caspase 3, and suggest that IU1 may be neurotoxic and 
diminish intracellular ATP levels. 
We also establish that high IU1 concentrations (HIU1 25 µM) are significantly neurotoxic 
as expected, since HIU1-treatment stimulated calpain-dependent cleavage of a range of substrates. 
These findings suggest that HIU1-treatment induces cell death via necrosis and not apoptosis, since 
it induces calpain and not caspase 3 activation. Furthermore, HIU1 (25 µM) concentrations cause 
mitochondrial dysfunction reflected in significant decreases in intracellular ATP levels. Of 
relevance, we show that IU1 inhibits mitochondrial Complex I in vitro. Taking into account the 
high degree of flux control of mitochondrial Complex I over oxidative phosphorylation in neuronal 
tissues [56,80,98], inhibition of even a small fraction of the enzyme, may lead to a significant 
decrease in ATP production by mitochondria [192]. It cannot be excluded that IU1 inhibition of 
NADH oxidation results in a change of redox state of the mitochondrial matrix leading to an 
imbalance of ROS metabolism. PGJ2-treatment combined with IU1 exacerbated the detrimental 




We demonstrate that IU1-treatment (HIU1 >25 µM) impairs E1 and 26S proteasome 
activities, both of which are ATP-dependent [44,114,167,188]. HIU1 hinders the ubiquitination 
cascade by blocking its first step; i.e., HIU1 prevents ubiquitin-activation by the E1 enzyme, 
without decreasing free Ub levels. The combined treatment with PGJ2 and IU1 exacerbated E1 
dysfunction, compared to IU1 alone. Our data strongly support the view that IU1 prevents PGJ2-
induced accumulation of Ub-proteins, not by enhancing their turnover by the 26S proteasome, but 
instead by blocking the ubiquitination cascade causing lower levels of Ub-proteins to be formed. 
This would explain why proteasome substrates such as TDP-43 accumulate as ubiquitinated-TDP-
43 reflecting 26S proteasome inhibition (as discussed below), while little change was detected in 
bulk ubiquitin conjugates in IU1-treated non-neuronal cells [101].  
HIU1 elicited the demise of the 26S proteasome in neurons by diminishing its assembly, 
which partially correlates with ATP-depletion. Concomitant with the decline in 26S proteasomes, 
HIU1-treatment induced a rise in the activity and levels of 20S proteasomes; that is HIU1 mimicked 
the effects of mitochondrial inhibitors on proteasomal function, just as found for calpain-activation 
and ATP-depletion [78]. We speculate that the significant increase in 20S proteasome activity 
induced by HIU1-treatment, contributes to the reduction in menadione-induced accumulation of 
oxidized proteins in HEK293 cells [101]. Menadione is a highly toxic oxidant that elevates 
superoxide levels [50]. Upon ATP-depletion triggered by IU1-treatment it is possible that 20S 
proteasomes are recruited to promote turnover of oxidized proteins independently of ubiquitination 
[62,87]. Moreover, the 26S proteasome and the ubiquitination machinery are more vulnerable to 
oxidative damage than 20S proteasomes [154]. Autophagy is not likely to be involved in the 





As shown in the current studies, lowering Usp14 levels by siRNA or loss of Usp14 
exhibited by neuronal cultures from Usp14axJ mice, did not counteract or exacerbate the 
detrimental effects of PGJ2 on neurotoxicity, caspase 3-activation, caspase-dependent Tau 
cleavage and accumulation of Ub-proteins. These results are in agreement with studies with HeLa 
cells showing that siRNA for Usp14 alone had no effect on, for example, cell growth [94,96]. The 
combined siRNA approach to knockdown Usp14 and another DUB UCH37, was necessary to 
observe accumulation of Ub-proteins [94,96]. The functional relationship among multiple 
deubiquitinases in terms of substrate hydrolysis and protein homeostasis, in particular in neurons, 
requires further investigation.  
Finally, we confirm that PGJ2 alone induces the accumulation of Ub-proteins, which is 
consistent with previous studies showing that PGJ2 lowers 26S proteasome levels and activity 
[81,124], and inhibits some of the thiol deubiquitinases including UCH-L1 and UCH-L3 
[108,115], as well as Ub-isopeptidase activity [130]. We also show, for the first time, that PGJ2 
lowers E1~Ub thioester levels. This result is surprising since we have shown that drugs that lower 
E1~Ub thioester levels, such as IU1 (current study) and mitochondrial inhibitors [oligomycin and 
antimycin in [78]] do not cause accumulation of Ub-proteins in neurons. It is likely that the 
accumulation of Ub-proteins detected in PGJ2-treated neurons reflects its ability to inhibit 
deubiquitinases that may stabilize the Ub-proteins formed prior to E1~Ub thioester depletion.  
  In summary, our findings show that IU1 is neurotoxic and lowers neuronal ATP levels by 
inhibiting mitochondrial Complex I, leading to a decrease in E1~Ub thioester, Ub-protein, and 26S 
proteasome levels, as well as calpain activation. In addition, pharmacologic (with IU1) or genetic 
(with siRNA or by a spontaneous mutation in Usp14axJ mice) inhibition of Usp14 fails to protect 




that inhibiting Usp14 (aside from IU1) is beneficial against other conditions that disturb protein 
homeostasis. For example, inhibiting Usp14 with three specific RNA aptamers [single-stranded 
synthetic RNA molecules that act like “chemical antibodies” [45]] facilitated the degradation of 
Tau conditionally expressed in HeLa cells [103]. In agreement with our data, the latter study with 
HeLa cells established that IU1 (~167µM) is significantly cytotoxic [103].  We also established 
that neurons accumulate IU1 to a higher intracellular concentration than MEFs. Using mass 
spectrometry we determined that neurons accumulate IU1 to ~90% of the extracellular 
concentration, while MEFs were determined to accumulate IU1 to only 26% of the extracellular 
concentration. The reason for this discrepancy remains to be established, but it may explain why 
the neurons are more sensitive than the MEFs to IU1. In conclusion, due to the magnitude and 
diversity of the enzymes involved in the UPP, a detailed understanding of their reaction 
mechanisms and relationships in neurons is of the utmost therapeutic interest, since reducing the 
levels of aberrant proteins in neurons is highly relevant to neurodegenerative disorders, such as 
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Upregulation of cyclooxygenase-2 (COX-2) has emerged as an important determinant of 
the cytotoxicity associated with neuroinflammation in AD. Prostaglandins (PGs) are major 
products of cyclooxygenases, but their role in neurodegeneration is poorly understood. PGD2 is 
the most abundant prostaglandin in the brain and increases the most under pathological conditions. 
Specifically, cortical neurons in AD brains were shown to exhibit accelerated PGD2 synthesis. 
PGD2 is unstable and is converted to the highly neurotoxic PGJ2 by spontaneous dehydration. In 
preliminary studies to address the in vivo effects of PGJ2 we established a mouse model of 
neuroinflammation relevant to AD. PGJ2 (16.7ug/2ul/week, for 3 weeks) was bilaterally 
microinfused into the CA1 hippocampal brain region of aged (53 weeks of age) and young (12 
weeks of age) mice. Following one week of post-surgery recovery, all mice underwent a 12-day 
training period on the radial 8-arm maze (RAM) to assess spatial learning and memory. Our data 
revealed significant spatial learning and long-term memory deficits in aged PGJ2-treated mice, 
compared to the other three groups. Hippocampal Fluoro-Jade C staining identified a significant 
increase in degeneration neurons in the CA3 region of aged PGJ2-treated mice, indicating a 
progressive spread of damage from the site of injection to the adjacent sub-region. Golgi-
immunohistochemical analysis identified a significant deficit in the expression of plasticity-related 
spine types, stubby and filopodia, within CA1 dendrites of aged-PGJ2 treated mice compared to 
the young-PGJ2 condition. This deficit occurred concomitantly with a significant increase in 
colocalization of synaptic markers GluA2/PSD95 within these spine types, indicating a deficit in 
maturation of spines via disrupted molecular trafficking and turnover. Our findings indicate that 
PGJ2, as a product of inflammation, can initiate neurodegeneration as well as facilitate its 




are highly relevant to AD pathology. We also assessed the efficacy of elevating endogenous cAMP 
as a therapeutic intervention in our model. Accordingly, a group of aged mice received PGJ2 
injections at the same time as PACAP27, a lipophilic neuroprotective peptide that raises 
intracellular cAMP. PACAP27 treatment ameliorated PGJ2-mediated learning and memory 
deficits on the RAM. We propose that this pre-clinical mouse model is highly valuable to identify 
and optimize therapeutics that suppress the neurotoxic effects of inflammation as a strategy to 
















3.2. INTRODUCTION  
Neuroinflammation is a defense process activated upon CNS injury to initiate repair 
mechanisms acutely, while chronic neuroinflammation can exacerbate, spread and prolong CNS 
injury. Chronic neuroinflammation is implicated in a variety of neurological and 
neurodegenerative disorders including AD [58,70,113]. Neuroinflammation is an active process 
detectable in the earliest and latest stages of AD [110,204,207].  
Cyclooxygenases (COX -1, constitutive and COX-2, inducible), which are key enzymes in 
the conversion of arachidonic acid into bioactive prostaglandins (PGs) play a central role in the 
inflammatory cascade. Inhibiting cyclooxygenases with non-steroidal anti-inflammatory drugs 
(NSAIDs) is being explored as a therapeutic strategy to mitigate chronic neuroinflammation and 
prevent the onset/progression of AD pathology [92,194]. NSAIDs’ effectiveness could be 
compromised as they block the generation of all prostaglandin products of cyclooxygenases. 
Prostaglandins act as potent local regulators of physiologic and pathologic pathways linked to CNS 
inflammation. We focused our studies on PGJ2 because it is highly neurotoxic compared to PGA1, 
D2 and E2 [108]. J2 prostaglandins including PGJ2, are endogenous toxic products of 
cyclooxygenases actively involved in neuronal dysfunction [47]. 
PGJ2 is a product of spontaneous non-enzymatic dehydration of PGD2, which is the most 
abundant prostaglandin in the brain [190], and undergoes the most changes under pathological 
conditions [109]. Specifically, cortical neurons in AD brains were shown to exhibit accelerated 
PGD2 synthesis [82] [202]. PGD2 is unstable as its half-life in the brain is 1.1 min and in the blood 
0.9 min, and some of it is converted to PGJ2 [185]. In rodents, the in vivo concentration of free 




100nM range [115,116], which are levels shown to be neurotoxic in vitro [72,97].These 
concentrations represent average brain levels, but local cellular and intracellular concentrations of 
PGJ2 are potentially higher [117], as PGJ2 binds covalently to proteins [190]. Therefore free PGJ2 
does not represent its total amounts.  
  PGJ2 signals in part via one of the PGD2 receptors, i.e. the DP2 receptor [68,126]. DP2 is 
coupled to inhibitory G-proteins thus lowering cAMP [68], and we confirmed that PGJ2 indeed 
lowers neuronal cAMP levels [124]. In an effort to overcome the cAMP deficit induced by PGJ2, 
we showed that raising intracellular cAMP levels with PACAP overcomes some of the neurotoxic 
effects of PGJ2 in rat cerebral cortical neuronal cultures [124], and in mice exhibiting 
parkinsonian-like pathology upon microinfusion of PGJ2 into the substantia nigra [176]. 
PACAP27  is a lipophilic peptide that binds to the seven transmembrane G-coupled receptor 
PAC1R (pituitary adenylate cyclase 1 receptor) at nanomolar levels, activating adenylate cyclase 
and elevating cAMP [127]. PAC1R is expressed in the cerebral cortex and hippocampus as well 
as other brain areas [88]. Overall, PACAP may offer a novel therapeutic approach to treat AD 
because it not only ameliorates some of the pathological processes observed in AD models, but it 
also diminishes some of the clinical symptoms of AD [203]. 
 To examine the in vivo effects of PGJ2 relevant to AD, we microinfused PGJ2 into 
hippocampi of aged (53 weeks of age) and young (12 weeks of age) mice. We included two 
different age groups in our study because the single greatest risk of developing AD is aging [69], 
with an exponential increase in cases after the age of 65 [15]. Moreover, steep age-related declines 
in synaptic density and plasticity make the brain increasingly less efficient. Our findings indicate 
that PGJ2, as a product of inflammation, can by itself initiate neurodegeneration as well as its 




relevant to AD. Furthermore, PACAP27 diminished some of the memory deficits induced by 
PGJ2. Like other toxic and genetic models, our new in vivo mouse model has limitations. 
However, it provides a tool to test neuroprotective strategies with fewer undesirable side effects, 
like PACAP27, applicable to AD and other neurodegenerative disorders in which the 






















3.3. MATERIALS AND METHODS 
3.3.1. Materials - Drugs: PGJ2 (cat. # 18500, Cayman Chemical) in DMSO, and PACAP27 
(pituitary adenylate cyclase-activating polypeptide, cat. # H-1172, Bachem Bioscience) in sterile 
water. The final DMSO concentration in PBS was 17% for all microinfusions. The solutions were 
freshly prepared and stored for a maximum of 2 h at 4 °C and in the dark.  
  Primary antibodies: GluA2, 1:1000 cat# MAB 397, EMD Millipore, PSD95, 1:1000, cat# 
AB9708, EMD Millipore.  Secondary antibodies: Alexa Fluor 568 (1:100, cat.# A11036, rabbit) 
and Alexa Fluor 488 (1:100, cat.# A11029, mouse) both from Invitrogen. Vectashield Hard Set™ 
mounting medium with DAPI (cat.# H-1500, Vector Laboratories).  
3.3.2. Mice - All procedures were performed in accordance with the NIH Guidelines for the Care 
and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committees at Hunter College. We included male B6-M (C57BL/6NTac) mice from Taconic 
farms, ages - young (12 weeks of age) and aged (53 weeks of age), to mimic an aging paradigm. 
Mice were singly housed on a 12h light/dark cycle with food and water available ad libitum, and 
were habituated for one week before treatment. All mice were microinfused bilaterally into the 
hippocampal CA1 region. Each mouse was injected once/week (Fig.14) with DMSO or PGJ2 
(16.7μg in 2µl DMSO) for three weeks (3 total injections). After behavioral analyses, mice were 






3.3.3. Stereotaxic surgery - We followed the same procedures as described in our previous study 
[148], except that mice received bilateral injections of vehicle (DMSO) or drugs (PGJ2 and 
PACAP27) into the hippocampal CA1 subregion. Briefly, at the respective ages (12 weeks for the 
young and 53 weeks for the middle-age), mice were anesthetized by isoflurane inhalation 
(induction 2–2.5%, maintenance 1.5–2%) administered in 100% oxygen and placed into a 
stereotaxic frame (Model 51730D, Stoelting Co., Wood Dale, IL) fitted with a gas anesthesia mask 
(Model 50264, Stoelting Co.). A burr hole was drilled in the skull at coordinates relative to bregma 
for the hippocampal CA1 subregion: rostral-caudal -2.0mm, medial-lateral +/- 1.0mm, dorsal-
ventral +1.5mm, as specified in the mouse brain atlas [49]. A 2 μL microinjection Hamilton 
syringe (7002 KH) with a 25-gauge needle was slowly inserted into the brain and left in place for 
five minutes. Thereafter, 2 μL of solution was infused at an injection rate of 0.2 μL/min 
(Quintessential stereotaxic injector, Model 53311, Stoelting Co.). The needle was left in place an 
additional five minutes to ensure total diffusion of the solution. Following injection, the needle 
was slowly removed and the incision was closed with monofilament absorbable sutures (cat. # 
033899; Butler Schein Animal Health, Dublin, OH). After surgery, mice were administered a 
subcutaneous injection of 0.5 cc Lactated Ringer's solution, given wet palatable rodent chow, and 
Figure 14. In vivo treatment and behavioral analysis outline. Groups of mice at two distinct ages (12 weeks and 
53 weeks) were injected bilaterally with (16.7µg/2µl) of PGJ2 or DMSO into the CA1 region of the hippocampus. 
Mice underwent radial 8-arm maze (RAM) training. 4 arms were baited/trial (*). There were 6 consecutive 
trials/day. 
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kept in a warm place to recover. Subsequent injections were administered via the same drill hole 
established during the first surgical procedure. 
3.3.4. Groups - Mice were randomly assigned to the treatment groups (Fig. 14). Mice in each age 
group received three bilateral injections (once/week for three consecutive weeks) of DMSO/PBS 
(n = 5 aged mice, n = 5 young mice) or PGJ2 (16.7μg in 2µl DMSO/PBS, n =5 aged mice, n = 4 
young mice) per injection. To assess the therapeutic efficacy of PACAP27, groups of aged mice 
received the same number of injections including PACAP27 (50 ng/2μL n =5), or 
PACAP27 + PGJ2 (n = 6) and were compared to those mice that received DMSO or PGJ2 only.  
3.3.5. The radial 8-arm maze (RAM) (Fig. 14) – RAM is a behavioral task used to evaluate long-
term reference and short-term working memory simultaneously [168,170,171]. Briefly, mice were 
food restricted to 85% of free-feeding weight. To acclimate mice to the maze prior to training each 
mouse received three exposures/day (2 days) to the maze with all arms baited (10min intervals, 
followed by 1h in home cage). During training, four of the 8 arms were baited with wet sweetened 
oatmeal (Maypo Inc, NJ) as previously described [168,170,171]. The sequence of baited arms 
remained fixed for each mouse. To avoid the use of internal maze cues, each day the maze was 
rotated 90o keeping the position of the baited arms stationary with respect to the room cues. Mice 
received 6 consecutive trials per day lasting no more than 3min per trial. To establish the trial % 
correct score, we divided the number of food rewards collected by the total number of arms 
entered. Reference and working memory errors were also scored. Reference memory errors occur 
when a subject entered an arm that is never baited. Reference memory is also associated with long-
term memory performance, thus the more correct arms entered during training, the better long-
term memory the mouse has. Working memory errors were committed when a subject re-entered 




3.3.6. Fluoro-Jade C analysis - Following behavioral analyses, mice were terminally anesthetized 
(i.p.) with ketamine (100 mg/kg) and acepromazine (3 mg/kg), and transcardially perfused with 
4% paraformaldehyde in PBS. The mouse brains were removed, post-fixed overnight at 4 °C, 
followed by cryoprotection (30% sucrose/PBS at 4 °C). Brains were sectioned in the coronal plane 
using a freezing microtome at a thickness of 20 μm, and sections were collected serially along the 
rostrocaudal axis of the hippocampus. Tissue series were stored at 4 °C (TBS, pH7.4 plus 0.1% 
sodium azide) until use. Each series was processed as free floating sections for Fluoro-Jade C 
analysis. Degenerating neurons/terminals were detected with Fluoro-Jade C (cat# AG325, 
Milipore) as described in [27,166].  
3.3.7. Quantification - Fluoro-Jade analysis: Under a wide-field fluorescence microscope (Zeiss 
AxioImager) the software AxioVision was used to capture whole hippocampal region mosaics 
(MosaiX capture mode). Exposure time for channel was kept constant between sections. For each 
captured image, ZVI files were load onto Image J (NIH, Bethesda, MD). Hippocampal subfields 
were isolated, cropped, and saved as .tif files for use in intensity analysis Channel was thresholded 
to extract the positive signal from all [150]. Pixel data above 75th percentile intensity were 
measured for per square micron in each image crop.  
3.3.8. Simultaneous Golgi-Cox Immunohistochemistry (GC-IHC) - Hippocampal brain 
sections cut at a 50 µm were processed for GC-IHC (dendritic spines, GluA2, PSD95) as described 
in [179]. LSCM (laser scanning confocal microscopy) with a Zeiss LSM 510 laser-scanning 
confocal microscope and 3D analysis: Z-stacks (4-6 µm; Z-step size 0.041 µm for CA1) were 
acquired of CA1 (15-75 µm in length, projecting into striatum radiatum). For 3D analysis, IMARIS 
7.5 (Andor Technology; Belfast, Northern Ireland) was used to analyze spines, determine spine 




3.3.9. Statistics. All data are expressed as the mean ± SEM. Statistical analyses were performed 
with GraphPad Prism 6 (GraphPad Software, San Diego, CA). A p-value < 0.05 was considered 
statistically significant. For group comparisons, we performed one-way or two-way analysis of 




3.4.1. PGJ2 delays spatial learning in aged compared to young mice - Previous data from our 
lab with rat E18 cerebral cortical neuronal cultures showed that PGJ2-treatment causes AD-like 
molecular pathological events, such as accumulation of ubiquitinated proteins, formation of ΔTau 
which is the major component of neurofibrillary tangles, formation of Ub-protein aggregates, and 
caspase-3 activation [124]. We were interested in investigating whether PGJ2 would induce AD-
like behavioral deficits in an age-dependent manner in a mouse model.   
  We observed that aged (53 weeks of age) PGJ2-treated mice performed worse in the radial 
arm maze (RAM) compared to the other 3 groups tested. The results obtained can be represented 
as % correct arm entry, and reference memory errors. Reference memory error occurs when a 
mouse enters an arm that is never baited. Behavioral analysis revealed that aged PGJ2-treated mice 
scored the lowest amount of correct arms entry of all the 4 groups tested which translates into their 
decreased learning and memory (Fig. 15 A and B). This correlates well with reference memory 
error analysis. Aged PGJ2-treated mice had the highest number of reference memory errors 
meaning that they entered arms that were never baited much more frequently than mice from the 




  There was no significant age difference in performance between DMSO-treated animals. 
As shown in Fig. 15A mice injected with DMSO learned the radial arm maze (RAM) over 12 days 
of training. Conversely young PGJ2-treated mice learned significantly better than aged PGJ2-
treated mice (Fig 15B). While all groups of mice showed significant improvement in their % 
correct scores over training days, the aged PGJ2-treated mice appear to reach a lower level of 
asymptotic performance at 65% correct. This learning deficit in aged PGJ2-treated mice is also 




















































































Figure 15. PGJ2 delays spatial learning in old compared to young mice. (A) DMSO treated mice learn 
equivalently showing a significant effect of training (F11,44 = 7.47, p < 0.001) without an effect of age. (B) 
PGJ2-treated mice show a significant overall effect of training (F11,110 = 18.92, p < 0.001), age (F1,10 = 13.76, 
p = 0.004), and a training by age interaction (F11,110 = 3.72, p < 0.001). Posthoc analysis for training days 1, 8, 
11 and 12 showed significance (*p < 0.01). (C) Average Reference Memory Errors (RME) per trial were not 
different between young and aged DMSO mice. (D) Aged PGJ2 mice averaged more Reference Memory 





3.4.2. PGJ2 affects long-term memory retention in aged compared to young PGJ2-treated 
mice - Long-term memory formation is known to be affected in AD patients. Therefore we 
investigated if PGJ2 impaired memory retention in mice one week after completion of the 12 days 
long training period. We found that PGJ2 impaired long-term memory in aged compared to young 
mice. Six days after the last training trial all mice were given another 6 trials. The days average % 
correct scores show that PGJ2-treated mice had significantly lower % correct scores than all other 







Figure 16. PGJ2 affects long-term memory in aged compared to young mice. Six days following the last 
training, mice were given an additional 6 trials. (A) The % correct scores show a significant overall effect of 
age (F
1,14 
= 5.56, p = 0.03) and an age by drug interaction (F
1,14 
= 7.56, p = 0.015), with no overall effect of drug 
treatment. Post-hoc analysis showed significance (*p = 0.05). (B) Aged PgJ2-treated mice performed 















3.4.3. PGJ2 induces hippocampal damage that spans from CA1 to CA3 only in aged PGJ2-
treated mice - We next analyzed changes at the cellular level in the hippocampus. PGJ2 induced 
a higher level of neurodegeneration in the hippocampus of aged compared to young mice as shown 













Figure 17. PGJ2 induces hippocampal 
damage that spans from CA1 to CA3 only 
in aged mice. Fluoro-Jade staining analysis 
(% DMSO) ran only on PGJ2 groups shows 
an overall significant effect of subregion 
CA1 vs CA3 (F
1,20
 = 9.67, p = 0.006). No 
significant age effect and a significant age by 
subregion interaction (F
1,20
 = 5.96, p = 0.02). 
Significant posthoc analysis within CA3 
subregion (*p<0.05) Scale bar, 100 µm. 




















3.4.4. PGJ2 induces dendritic spines defects in the hippocampal CA1 region of aged mice - 
Dendritic spines are protrusions in post-synaptic compartments and are sites of synaptic 
transmission. Each spine receives input from excitatory synapses and due to the presence of 
neurotransmitter receptors, organelles and signaling cascades it has the ability to establish and 
maintain the synapse. The presence of dendritic spines is linked to memory formation and defects 
in their number and types are linked to memory deficits in various neural disorders, such as AD. 
Spines are dynamic structures; their plasticity and remodeling are associated with learning. There 
are four main types of spines, stubby, filopodia, long-thin and mushroom) (Fig. 18), characterized 
by their developmental profile ranging from immature (stubby, filopodia) to mature (long-thin, 








Figure 18. Dendritic spine types and characteristics A, Spine types as characterized by [75]: 
(Left to right) stubby, filopodia, long thin, and mushroom. Spines demonstrate a dynamic 
developmental profile. Plastic, immature spines (stubby and filopodia) lack post-synaptic 
density and AMPARs. Stable, mature spines (long-thin, mushroom) express higher levels of 
synaptic markers. IMARIS XT parameters for spine detection using the spine classification 
module. B, Parameters were based on relative spine neck and head relationships as in [12,124]. 
Representative Golgi-Cox IMHC dendrites for control conditions (scale bar = 5 μm for C; 3 
μm for D. Golgi-Cox indicated in green, colocalization of synaptic markers in yellow. Red 





The size of the spine head dictates whether the spine is immature and plastic or mature and stable. 
Spines that have large mushroom-shaped heads are considered established, “memory” spines. 
Characterizing spine morphology with Golgi-IHC is an innovative approach that allows the 
coupling of immunohistochemistry with Golgi-Cox staining visualized with confocal microscopy 
[179]. Our studies using this technique, identified a significant decrease in the total number of 
dendritic spines in the hippocampal CA1 region of aged (Fig. 19 A) compared to young PGJ2-
treated mice. This result indicates deficits in memory and corroborates the findings of our 
behavioral analyses. Moreover, aged PGJ2-treated mice have less stubby and filopodia spines in 
the CA1 dendrites (Fig. 19 B and C), suggesting that PGJ2 impaired spine plasticity that could 











Figure 19 (A). Dendritic spine analysis. Using a Leitz 
Diaplan microscope, a Nikon DXM 1200F camera, and 
Image Pro Plus software (Media Cybernetics, Bethesda, 
MD, USA), dendritic spine density on pyramidal cells from 
the CA1 region of the dorsal hippocampus and layer II/III 
of the mPFC were analyzed. Regions were defined based 
on The Mouse Brain in Stereotaxic Coordinates (Franklin 
KBJ, Paxinos G: 1997) and counting was done as described 
by Frankfurt et al (Dev Neurosci. 2009;31(1-2):71-5). 
Images of tertiary dendrites projecting into the stratum 
radiatum of CA1 (15-95 μm in length) and in CA3 (20-95 
μm in length) were captured using a Leica SP2 confocal 
microscope. Spine morphology and expression of synaptic 




























  Mature spines have well established post-synaptic densities (PSD), which are zones close 
to the membrane that consists of neurotransmitter receptors, channels and systems involved in 
synaptic transmission (Fig. 20). One of the markers of a fully developed, mature spine is PSD95, 
a scaffold protein that determines structural and functional integrity of excitatory synapses [16]. 
The other marker is GluA2, a subunit of an AMPA glutamate receptor which is critical for synaptic 
plasticity. We assessed the levels of both of these synaptic markers because their co-localization at 
the post-synaptic terminal labels an active, mature synapse associated with formed memories. Our 
analysis revealed increased levels of GluA2 and PSD95 in stubby (immature) spines in the CA1 
region of aged compared to young PGJ2-treated mice (Fig. 20). This unexpectedly high level of 
mature synaptic markers in plastic spines may indicate disrupted protein trafficking resulting in 
their inability to mature into memory-associated spines, i.e. long-thin and mushroom types, which  
B C
Figure 19. Dendritic spine analysis. (B) Aged-PGJ2 treated mice display significantly less plastic spines 
(stubby and filopodia), (C) Aged-PGJ2-treated mice display less mature spine types than young PGJ2-treated 






















































Figure 20. IHC analysis of dendritic spines (A) GluA2 and (B) PSD95 levels are significantly 
increased in stubby spines in aged PGJ-treated mice. (C) Significantly increased colocalization of 
GluA2 and PSD95 in stubby spines in aged PGJ2-treated mice. (D) Representative Golgi-Cox IMHC 
dendrites for control conditions (scale bar = 5 μm. Golgi-Cox indicated in green, co-localization of 










































3.4.5. PACAP27 prevents learning and memory deficits induced by PGJ2 in aged mice.  
We investigated if neuroprotective peptide PACAP27 could prevent learning and memory 
retention loss in PGJ2-treated mice (Fig. 21). PACAP did prevent learning deficits in aged PGJ2-
treated mice to a certain extent. The % correct arm entry was higher for aged PGJ2/PACAP-treated 
mice from day 3 to day 12 of RAM training than PGJ2-treated mice. On day 9 the difference 
between the two groups was statistically significant (p value = 0.0107). Aged mice injected with 
























Figure 21. PACAP27 prevents learning and memory deficits induced by PGJ2 in 
aged mice. Mice underwent 12 day learning period on RAM. %correct arm entries for 
all the mice from all cohorts on a particular day was averaged as represented in (A) 
and (B). 6 days after completing last training, mice were subjected to additional 6 trials 
and their performance from that day is represented in (C) and (D) 






















































One of the earliest clinical hallmarks of AD is progressive memory impairment.  Patients 
suffering from this debilitating condition exhibit loss of spatial memory and are unable to orient 
themselves with respect to physical surroundings. This memory symptom correlates with neuronal 
death in the hippocampus, the brain region responsible for learning, spatial orientation and memory 
storage. AD-relevant memory loss can be recapitulated in mouse models and is easily examined 
as there are numerous, well established behavioral assays available to test memory in rodents. 
Studies showed that a lesion in hippocampal CA1 region in rats is sufficient to produce memory 
impairment [84]. The causes of initial pathology of AD are not yet understood but there is 
consensus in the scientific community that chronic neuroinflammation plays and important role in 
neurodegeneration.   
We focused our investigations on the product of inflammation PGJ2 because it is highly 
neurotoxic [108], and its levels have been shown to increase upon pro-inflammatory stimuli such 
as brain injury (ex. stroke and TBI) [97],[72], which is a well-established risk factor for AD.  Our 
preliminary studies indicate that microinfusion of the cyclooxygenase product of inflammation 
PGJ2 into the CA1 region of the hippocampus initiates neurodegeneration as well as its 
progression within the hippocampus in an age-dependent manner, thus mimicking pathology that 
are highly relevant to AD. 
As memory and cognitive impairment are central problems in AD, we used behavioral tests 
to characterize spatial learning and memory deficits induced by PGJ2 over time in aged (53 weeks 
of age) and young (12weeks of age) mice.  Our preliminary studies show that PGJ2 impaired long-




hippocampus of aged mice compared to young mice as shown with Fluoro-Jade C staining. PGJ2 
also decreased synaptic plasticity in aged mice, which could explain learning impairment. The 
behavioral deficits induced by PGJ2 were correlated with the colocalization of specific synaptic 
markers within various spine types. Trafficking of the GluA2 receptor subunits to the postsynaptic 
density increases during episodes of synaptic plasticity, and stabilizing AMPA receptors within 
the synaptic membrane is important for memory consolidation [169].  Our analysis revealed that 
GluA2 (subunit of the AMPA receptor) as well as PSD95 (postsynaptic density marker) were both 
significantly higher in the stubby spines of aged-PGJ2 treated mice. This novel finding could 
indicate that PGJ2 impairs the ability of plastic spines to mature into memory associated spines, 
resulting in memory deficits in-vivo.  
We also showed that the neuroprotective peptide PACAP27 prevented to a certain extent 
learning and memory impairment induced by PGJ2 in aged mice. These studies require further 
analysis, for example assessing whether PACAP could prevent PGJ2-induced neurodegeneration 
as well as dendritic spine deficiencies. Overall, our data indicate that targeting PGJ2 by increasing 
cAMP levels with PACAP27 may be an efficient therapeutic approach to prevent PGJ2-dependent 
neurodegeneration and memory deficits.  
 Our investigation of the neurotoxic pathway and mechanisms by which PGJ2 leads to 
neurodegeneration underscores its relevance as a risk factor mediating the long-term effects of 
neuroinflammation in the progression to AD. Targeting factors downstream of cyclooxygenases, 
such as PGJ2, offer great promise as a new therapeutic strategy that would not alter the homeostatic 






























Sporadic Alzheimer’s disease (sAD) is an age-related neurodegenerative disorder. Its 
causes are largely unknown but evidence supports that a combination of environmental and 
lifestyle factors can cause recurring inflammatory insults that contribute to chronic 
neuroinflammation and neuronal death. Despite decades of research it is still not known how to 
prevent, slow down or cure AD. Medicine that is currently available for AD patients offers only 
temporary, symptomatic relief [52]. Current research on AD focuses on developing new imaging 
tools that facilitate detection of pathological changes in the brain early enough to start treatment 
that would prevent neurodegeneration [87]. Another research focus is on developing new 
therapeutic strategies. These two areas of investigation need to go hand in hand for advancement 
and efficient treatment of AD.  
UPP is essential for maintaining cellular homeostasis as it is involved in a number of 
cellular processes, such as neuronal homeostasis, synaptic plasticity, signal transduction, and 
mitochondrial dynamics. Impairment of this proteolytic pathway has long been associated with 
AD.  Agents that increase the efficacy of the UPP could improve proteasomal function and prevent 
accumulation and aggregation of Ub-proteins, both of which are hallmarks of AD.  
Our studies focused on examining two new potential therapeutic targets related to the UPP:  
a) The Usp14 deubiquitinating enzyme – we investigated whether its inhibition 
increases proteasome-dependent degradation and decreases toxicity induced by the 
endogenous product of inflammation PGJ2.                
b) The product of inflammation PGJ2 that impairs different steps of the UPP – we 
investigated whether PGJ2 induces AD-like neuronal and behavioral pathology in vivo, by 




potential of PACAP to overcome the deleterious effects of PGJ2. 
a) Studies with the Usp14 deubiquitinating enzyme: 
We attempted to increase proteasome-dependent degradation by inhibiting the Usp14 
enzyme using pharmacological and genetic approaches. The Usp14 deubiquitinating enzyme 
slows down protein degradation by removing ubiquitin tags too soon, allowing the substrate to 
prematurely dissociate from proteasomes thus avoid degradation. Studies from other groups 
showed that inhibiting Usp14 in MEFs and HEK cells with the small molecule inhibitor IU1 
increased the degradation of proteasome substrates implicated in neurodegenerative diseases, such 
as Tau, TDP-43 and ataxin-3 [101]. In our studies, we investigated the effects of IU1 on rat E18 
cerebral cortical neuronal cultures, a cell model that is much more physiologically relevant to AD 
than MEFs or cancer cell lines such as HEK cells. Treatment of primary neurons with high 
concentration of IU1 (75 µM) decreased the levels of Ub-proteins induced by PGJ2, suggesting 
that inhibiting Usp14 with IU1 indeed enhanced Ub-protein degradation and prevented their 
accumulation. However, this result was accompanied by other thought provoking data. Our studies 
showed that IU1 (75 µM) treatment in neurons activates calpain-dependent cleavage of Tau, 
spectrin and caspase-3 and decreases the levels of 26S proteasomes with a concomitant increase 
in 20S proteasomes. These findings suggested that IU1 could have off target effects. We confirmed 
this by demonstrating that IU1 inhibits mitochondrial complex 1 leading to mitochondrial 
impairment and ATP deficits. In addition, we established that Usp14 knockdown by siRNA in rat 
neuronal cultures, or Usp14 loss in Usp14axJ mouse neuronal cultures did not change the levels of 
Ub-proteins induced by PGJ2. These data strongly support the view that IU1 prevents PGJ2-
induced accumulation of Ub-proteins, not by enhancing their turnover by the 26S proteasome, but 




While our studies focused on investigating the properties of a new potential therapeutic, 
we had another unexpected finding. We showed, for the first time to our knowledge, that PGJ2 
lowers E1~Ub thioester levels. This result is surprising since we have shown that drugs that lower 
E1~Ub thioester levels, such as IU1 (current study) and mitochondrial inhibitors (oligomycin and 
antimycin in [78]) do not cause accumulation of Ub-proteins in neurons. It is likely that the 
accumulation of Ub-proteins detected in PGJ2-treated neurons reflects its ability to inhibit 
deubiquitinases that may stabilize the Ub-proteins formed prior to E1~Ub thioester depletion. 
In conclusion, the functional relationship between the enzymes and components of UPP 
requires further investigation as detailed understanding of their interactions are of the utmost 
therapeutic interest since reducing the levels of aberrant proteins in neurons is highly relevant to 
neurodegenerative disorders, such as AD. 
 
 
 Figure 22. 
Model 1.  
IU1 impairs 
mitochondria 
which leads to 











b) Studies with the product of inflammation PGJ2 that impairs different steps of the UPP. 
Chronic inflammation is emerging as a major factor involved in AD pathogenesis and its 
progression. Chronic inflammation is manifested by activated microglia and astrocytes that release 
neuroprotective and neurotoxic factors. Some of these factors are produced by cyclooxygenases, 
key enzymes in the conversion of arachidonic acid into prostaglandins. Our previous studies 
showed that PGJ2 is a highly toxic product of COX-2 [108], the levels of which increase upon 
brain injury and during neurodegeneration [110],[7].  PGJ2 belongs to the cyclopentenone 
prostaglandin family. These PGs are unique in that they form covalent Michael adducts by binding 
to free sulfhydryl groups on proteins thus modifying them and potentially impairing their structure 
and function. This pathogenic process can contribute to neurodegeneration, in particular because 
PGJ2 impairs the UPP by different mechanisms, such as inhibiting UCH-L1 the most abundant 
deubiquitinating enzyme in the brain, as well as disrupting 26S proteasome assembly [198]. 
Epidemiological studies suggest that patients taking non-steroidal anti-inflammatory drugs 
(NSAIDs) are at a reduced risk (by as much as 50%) for developing AD, although this notion is 
controversial. NSAIDs target cyclooxygenases thus inhibit formation of all downstream 
prostaglandins including neuroprotective ones. Additionally, inhibiting COX-1 and COX-2 was 
shown to have side effects such as renal failure and stroke [140]. Therefore, we postulated that 
taking a more directed approach and targeting PGJ2, a neurotoxic prostaglandin that is downstream 
of COX-2 would be of more benefit.  
To test this hypothesis PGJ2 (16.7μg in 2µl/week, for 3 weeks) was bilaterally 
microinfused into the CA1 hippocampal region of aged (53 weeks) and young (12 weeks) mice. 
Our preliminary data established that PGJ2-treatment caused a) memory deficits, b) degeneration 




in the CA1 region. We also found that these pathological changes were age-dependent being 
detected in aged but not young PGJ2-treated mice. These results strongly support the view that 
PGJ2 by itself is sufficient to induce AD-like neuronal and behavioral pathology, and suggest that 
inhibiting its activity would be a beneficial therapeutic approach. The benefit lays in the fact that 
expression of other neuroprotective prostaglandins would not be affected by this approach, and 
perhaps side effects stemming from prolonged usage of NSAIDs could be avoided.   
Our in vivo studies with PGJ2 are very promising but we still need to address other 
potential mechanisms by which PGJ2 disturbs neuronal homeostasis to broaden our understanding 
of the impact that inflammation has on the brain (discussed in Future Directions). In addition, our 
studies could contribute to developing an AD model of inflammation that could serve as a platform 
for testing neuroprotective drugs. To this end, we concluded our studies with briefly testing the 
neuroprotective peptide, PACAP27 as a potential therapeutic for AD. We demonstrated that co-
administration of PACAP27 and PGJ2 mitigates some memory impairment induced by PGJ2 
treatment, although this change is not statistically significant.  PGJ2 signals via the DP2 receptor, 
which is coupled to inhibitory G proteins that lower intracellular cAMP [68], [76], [126]. We and 
others previously demonstrated that PACAP treatment of neuronal cultures overcomes the 
decrease in cAMP levels induced by PGJ2 [124], [178]. This approach requires further 
investigation to assess whether PACAP27 protects against PGJ2-induced neurotoxicity. 
In conclusion, the potential therapeutic strategies we investigated here offer new insights 
into mechanisms of AD development and if further explored could potentially prevent 








































Many neurodegenerative disorders, including AD are related to the abnormal accumulation 
of symptomatic proteins. For example in AD it is truncated Tau – ΔTau - that is deposited in 
neurofibrillary tangles. A decrease in protein turnover is associated with impaired UPP. 
Maintaining protein homeostasis presents a critical task in post-mitotic neuronal cells. Therefore, 
developing new strategies aimed at enhancing or preserving the function of the UPP as well 
preventing neurotoxicity is essential for substantial therapeutic efficacy. 
Inhibiting Usp14 was not effective in our cell model, i.e. rat E18 cerebral cortical neuronal 
cultures. Moreover, other investigators showed that Usp14 null mice (ataxia mice) exhibit 
developmental abnormalities including motor impairment, reduced brain mass and death by 2 
months of age [25]. This proves that targeting any component of such a complex pathway like the 
UPP requires detailed knowledge of its function and understanding of its interactions with other 
elements. Furthermore, the small molecule inhibitor of Usp14, i.e. IU1, turned out to have an off-
target effect by inhibiting mitochondrial complex 1 thereby causing mitochondrial impairment and 
ATP deficits. Since many exogenous, small molecules have off-target effects that are difficult to 
predict we suggest employing other strategies. 
We propose the following: 
1) Investigate increasing UPP function and preventing neurotoxicity by using 
neuroprotective peptides - Perhaps endogenous, neuroprotective peptides could be a better 
choice of potential therapeutics as unpredictable off-target effect would be avoided. Additionally 
a combination therapy involving more than one peptide could act in a variety of ways to prevent 
AD-related neurodegeneration. Studies from our group previously showed that one such peptide, 
PACAP27, diminishes PGJ2-induced toxicity in rat E18 cerebral cortical neuronal cultures via 




PACAP27 decreased caspase-3 activation, ΔTau formation, Ub-proteins levels and aggregation, 
and the loss of cell viability [124]. PACAP27 was also shown to be protective in vivo 
[30,32,36,42]. Overall, PACAP27 appears to be a good therapeutic as it alleviates many of the 
symptoms induced in our cell model of inflammation. However, AD is a multifactorial disease, so 
combining PACAP with other protective peptides that exert different functions could be of greater 
benefit.  Another potential therapeutic, (VEGF) is a vascular endothelial growth factor that 
promotes angiogenesis and neurogenesis both in vivo and in vitro [86,102,120]. VEGF's potential 
as a protective factor has been demonstrated in hypoxia–ischemia, in vitro excitotoxicity, and 
motor neuron degeneration [184], [182]. There are a number of neuroprotective peptides that could 
be explored such as AdNP (activity-dependent neuroprotective protein), which is a glial cell 
modulator of VIP associated neuroprotection and is implicated in maintenance of cell survival 
through modulation of p53 expression ([8], [177,208]).  AIP (autocamtide-related inhibitory 
peptide) was shown to inhibit Ca2+/Calmodulin dependent protein kinase II, Aβ-triggered 
activation of caspase 2 and 3, and Tau phosphorylation, as well as protect neurons against Aβ 
toxicity [111]. Patients with AD show a marked loss of cholinergic neurons and diminished 
Substance P expression [149]. Substance P is a short peptide that interacts with the cholinergic 
ascending system resulting in enhancement effects [1]. In conclusion, there are a number of 
endogenous neuroprotective peptides the levels of which are decreased in AD. They act in different 
ways and in different pathways. Therefore increasing their levels and using them in combination 







 2) Our studies would benefit from more detailed evaluation of PGJ2 toxicity in 
vivo. We propose to: 
a) Assess if PGJ2 causes microglia activation in hippocampus. Activated microglia 
are a hallmark of inflammation, therefore assessing their level of activation would allow us to 
determine if PGJ2 administration exacerbates the immune response in the hippocampus.  It would 
also allow us to investigate whether age exacerbates PGJ2-induced microglial activation. This 
would be carried-out by IHC analysis using IBA-1 as an activated microglia marker.  
b) Assess if PGJ2 induces caspase-dependent Tau cleavage and leads to the 
formation of ΔTau. Tau is a microtubule associated protein the function of which is to stabilize 
microtubules. However, during AD-related neurodegeneration it becomes hyperphosphorylated 
and cleaved by activated caspases 3 and 8 to aggregation-prone ΔTau which is a major component 
of neurofibrillary tangles. We previously showed that this is the case in rat E18 cerebral cortical 
neuronal cultures treated with PGJ2 [124]. It would be interesting to investigate whether PGJ2 
induces caspase activation and caspase-dependent Tau cleavage to ΔTau in our PGJ2-induced 
mouse model of neuroinflammation that exhibits AD-like pathology. 
c) Investigate if PGJ2-induced pathology could be prevented by delivering 
PACAP in vivo. We have already determined that PACAP co-injected with PGJ2 improves 
learning in aged mice, although this change is not statistically significant. It would be interesting 
to investigate if PACAP could prevent molecular and cellular pathological changes induced by 
bilateral injections of PGJ2 into the CA1 region of the hippocampus. We would assess microglial 
activation, degeneration, dendritic spines abnormalities and other parameters. The next step would 
be to administer PACAP27 intranasally to mice that have been previously injected with PGJ2. The 




investigators to successfully deliver a variety of therapeutics, like neurotrophic factors [185,191], 
cytokines [160,206], and neuropeptides [6]. Most importantly, intranasal delivery of PACAP has 
been shown to reduce β-amyloid plaques in an AD transgenic mouse model [152]. Intranasal 
delivery of therapeutics to the central nervous system (CNS) has the advantage that it bypasses the 
blood brain barrier (BBB) and systemic adversities [66]. Drugs get absorbed through the nasal 
mucosa and reach CNS via three potential pathways:  a) adsorptive or receptor-mediated 
endocytosis into olfactory sensory neurons (OSNs) followed by intracellular transport to the 
olfactory bulb; b) non-specific fluid phase endocytosis into OSNs followed by intracellular 
transport into the olfactory bulb; c) extracellular diffusion along the open inter-olfactory clefts 
directly to the olfactory bulb, then to the subarachnoid space and cerebrospinal fluid (CSF) [66] 
[34]. From the cerebrospinal fluid drugs are distributed throughout the brain.  Overall, intranasal 
delivery of PACAP provides a promising alternative to other routes of administration and is 
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